

Filed:

For:

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

§

§

Ş

Group Art Unit: 1644

Attorney

Docket: 30337

Oron YACOBY-ZEEVI et al

10/559.925 Serial No.:

HEPARANASE ACTIVITY NEUTRALIZING

ANTI-HEPARANASE MONOCLONAL

ANTIBODY AND OTHER ANTI-HEPARANASE ANTIBODIES

Examiner: DIBRINO, MARIANNE NMN

these citations of official record in this application.

02-May-2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of all other references have been received by the Examiner through corresponding applications. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make

Applicant requests that MPEP 609 III A(2)(E) be complied with and the examiner consider information which has been considered by the Office in a parent applications thereof. A listing of the references cited in those applications follows on the attached PTO/SB/08A. Applicant respectfully requests that they be made of record in the instant application.

This application is a National Phase Application of PCT Application No. PCT/IL2004/000477 having International Filing Date of June 3, 2004, which claims the benefit of U.S. Patent Application No. 10/456.573, filed on June 9, 2003 and U.S. Patent Application No. 10/645,659, filed on August 22, 2003. The contents of the above Application s are all incorporated herein by reference.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /M.D./

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Madu D Mognuha

Martin D. Moynihan

Registration No. 40,338

Dated: January 11, 2007



Sheet

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE action Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 27

(use as many sheets as necessary)

	- 1	•			
			U.S. PATEN'	T DOCUMENTS	
Examiner Initials*	Cite No. 1	Document Number  Number-Kind Code <sup>2</sup> (Wheen)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5,997,863	07-7-1999	Zimmermann et al.	+
	2	US-5,688,679	11-18-1997	Powell	
	3	US-6,387,643	05-14-2002	Heinrikson et al.	· · · · · · · · · · · · · · · · · · ·
	4	US-6,423,312	07-23-2002	Yacoby-Zeevi	-
	5	US-6,531,129	03-11-2003	Pecker et al.	_
	6	US-4,455,296	06-19-1984	Hansen et al.	
	7	US-5,571,506	05-5-1996	Regan et al.	
	8	US-5,917,830	06-29-1999	Chen et al.	
	9	US-5,859,660	01-12-1999	Perkins et al.	
	10	US-5,600,366	04-4-1997	Schulman	
	11	US-6,020,931	01-1-2000	Bilbrey et al.	
	12	US-6,153,187	11-28-2000	Yacoby-Zeevi	
	13	US-5,145,679	08-8-1992	Hinson	
	14	US-5,736,137	07-7-1998	Anderson et al.	
	15	US-5,194,596	03-16-1993	Tischer et al.	
	16	US-5,350,836	09-27-1994	Kopchick et al.	
	17	US-6,562,950	05-13-2003	Peretz et al.	
	18	US-6,699,672	02-2-2004	Pecker et al.	
	19	US-5,580.862	03-3-1996	Rosen et al.	
	20	US-5,474,983	12-12-1995	Kuna et al.	
	21	US-2002/0102560	8 94-1-2002	Pecker et al.	
	22	US-6,790,658	09-14-2004	Pecker et al.	
	23	US-6,798,658	09-28-2004	Takedomi et al.	
	24	US-5,618,709	08-8-1997	Gewirtz et al.	
	25	US-5,656,595	08-12-1997	Schweighoffer et al.	
	26	US-4,683,195	07-28-1987	Mullis et al.	
	27	US-5,602,095	02-11-1997	Pastan et al.	
	28	US-2004/0142427	07-22-2004	Pecker et al.	
	29	US-4,117,841	03-3-1978	Perrotta et al.	
	30	US-2003/0161823	08-28-2003	llan et al.	
	31	US-5,962,321	05-5-1999	Gough et al.	

\*EXAMINER: Install It reference considered, whether or not citation is in conformance with MPEP 000. Draw line through citation I not in conformance and not considered, include copyor clopy of this form with next communication to applicant.\* Applicant in single citation designation number 001, "See Kinds Codes of USPTO Patent Decuments of several communications and patents of the second of the second of USPTO Patent Decuments of several codes." I See Kinds Codes of USPTO Patent Decuments of several codes. The second of the secon

This collection of information is required by 3T CFR.197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO in proceed) an application. Confidentiality is governed by 38 U.S. C.12 and 3T CFR.1.4 this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete its fortion and/or suggestions for reducing this busden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commence, P.O. 80x 1459, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1459, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/559 925 INFORMATION DISCLOSURE Filing Date May 02, 2006 STATEMENT BY APPLICANT First Named Inventor Oron YACOBY-ZEEVI et al. Art Unit 1644 (use as many sheets as necessary) DIBRINO, MARIANNE NMN Examiner Name 30337 Attorney Docket Number Sheet 2 U.S. PATENT DOCUMENTS 32 US-5,830,759 03-3-1998 Chang et al. 33 US-6,230,151 08-8-2001 Agrawal et al 34 US-5,799,311 08-25-1998 Agrawal et al. US-6,314,420 06-6-2001 Lang et al. 36 US-4.937,747 06-26-1990 Koller US-6,307,965 10-23-2001 Aggarwal et al. Goiffon et al. 38 US-6,226,792 01-1-2001 39 US-5,859,929 01-12-1999 Zhou et al. 40 US-5,799,276 08-25-1998 Komissarchik et al. 41 US-2002/0068061 06-6-2002 Peretz et al. 01-1-1994 Weinshank et al 42 US-5,360,735 43 US-2002/0088019 <del>-94-</del>4-2002 Yacoby-Zeevi 12-31-1996 Drohan et al. 44 US-5,589,604 45 US-5,700,671 12-23-1997 Prieto et al. US-5,714,345 03-3-1998 Clark 46 US-5,716,817 47 02-10-1998 T?rnell 10-31-2000 Deboer et al. 48 US-6,140,552 Garofalo et al. 49 US-2003/0163836 08-28-2003 US-2002/0194625 12-19-2002 Zcharia et al. 50 US-6,190,875 02-20-2001 Ben-Artzi et al. US-2001/0006630 05-5-2001 Yacobi-Zeevi et al. 08-22-2002 US-2002/0114801 Pecker et al. 54 US-6,475,763 05-5-2002 Aval-Hershkovitz et al. US-6,426,209 07-30-2002 Ayal-Hershkovitz et al. 55 US-6,800,441 95-5-2004 Pecker et al. 56 US-2002/0168749 11-14-2002 Pecker et al. 58 US-2003/0068806 04-10-2003 Aval-Hershkovitz et al. 59 US-6.946.131 09-20-2005 Peretz et al. 60 US-2003/0181687 09-25-2003 Peretz et al US-6,960,471 01-1-2005 Pecker et al. 61 62 US-2003/0190737 09-9-2003 Pecker et al. 63 US-2003/0170860 09-11-2003 Pecker et al. 64 US-2003/0217375 11-20-2003 Zcharia et al 65 US-2004/0213789 10-28-2004 Yacobi-Zeevi et al. 66 US-2004/0063135 01-1-2004 Pecker et al. 67 US-2004/0146497 07-29-2004 llan et al.

\*EXAMINES: ritial if interance considered, whether or not calation is in conformance with MPEP 600. Draw fine through clattled in the conformance and not considered include copy of copy of this for with next communication to applicant. \*Applicant\*, single called nestinguistic copy of copy of this for with next communication to applicant. \*Applicant\*, single called nestinguistic copy of copy of the See Kinds Codes of USPTO Patient Documents at two useful or MPEP 901 04. \*Enter Office that issued the document, by the evo-letter code (PMPEP Standard ST.3). \*\*For Japanese patient document, the dictation of the year of the region of the Emperor must proceed the serial number of beart document. \*\*Arch of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

01-17-2006

68

US-6,986,996

This collection of information is required by 3T CFR.197 and 19.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO lo process) an application. Confidentiality is governed by 38 U.S. C.122 and 3T CFR.1.4 this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commence, P.O. 80x 1450, Alexandria, V.A. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, V.A. 22313-1450.

Pecker et al

PTO/SB/08a (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use through 07/37/2003, OMD 0031-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pa	perwork	Reduction Act of 1995, no persons	are required to i	espond to a co	Mection of info				_
	Substitute for form 1449A/PTO				Applicat	tion Number	lete if Kr 10/55		-
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				1. **				_
					Filing D		1 .		
					First Na	med Inventor	Oron	YACOBY-ZEEVI et al	
					Art Unit		1644		Т
				Examine	er Name	DIBR	INO, MARIANNE NMN	_	
Sheet		3 of 27			Attorney	Docket Number	30337		-
Silect		,	1		DOCUM				_
	- (0	US-2004/0146925	07-29-20		DOCUM	Pecker et al.			_
	70	US-2004/0146925 US-2005/0260187	11-24-20			Ilan et al.			-
			01-12-20			'acobi-Zeevi et al.			-
	71	US-2006/0008892				acobi-Zeevi et al.			-
	72	US-2003/0031660	02-13-20			Nicholson et al.			_
	73	US-4,859,581	08-22-19			Vlodavsky et al.			_
	74	US-4,882,318	11-21-19			Gallo et al.			_
	75	US-5,129,877	07-14-19				_		-
	76	US-5,206,223				Vlodavsky et al			-
	77	US-5,332,812	07-26-19			Nicolson et al. Fuks et al. Leshchiner et al Lormeau et al.			_
	78		98-8-199						_
	79	US-5,399,351	03-21-19						_
	80	US-5,550,116	08-27-19						_
	81	US-5,667,501	09-16-19		<u> </u>	Fowler et al. Fugedi et al			_
	82	US-5,739,115	04-14-19		<u> </u>				_
	83	US-6,348,344	02-19-20		Ay	al-Hershkovitz et a	l.		_
	84	US-4,946,778	08-8-199	)		Ladner et al.			_
			/			TIN ATTA INTO	1		_
Examiner	Cite		FOREIG	NPATE	NI DOC	UMENTS		Pages, Columns, Lines,	т
Exammer Initials*	No.	Foreign Patent Docu	ments		ation Date	Name of Patentee or		Where Relevant Passages	ı
		Country Code3- Number4- Kind C	ode <sup>5</sup> (if known)	MM-I	DD-YYYY	Applicant of Cited D	ocument	or Relevant Figures Appear	L
	85	PCT WO 95/04158		09-9-	1995	Hoogewerf et al.			L
	86	PCT WO 99/21975		06-6-	1999	Freeman et al.			1
	87	PCT WO 91/19197		12-12	-1991	Nicolson et al.			Ι
	88	PCT WO 95/04518		02-16	-1995	Midha et al.			Ι
	89	PCT WO 97/11684		03-3-	1997	Bennett et al.			Ι
	90	PCT WO 99/18852		04-22	-1999	Arenson			T
	91	PCT WO 91/02977		07-7-	1991	Fuks et al.			Τ
	92	PCT WO 97/27327		07-31	-1997	Van Ness et al.			Ι
	93	PCT WO 00/52149		08-8-	2000	Yacobi-Zeevi			
	94	PCT WO 00/52178		08-8-	2000	Pecker et al.			
	95	PCT WO 99/40207		08-12		Nakajima et al.			I
	96	PCT WO 98/46258			-1998	Bhaskar et al.			T
	97	EP 0254067			-1988	Cohen et al.			T

\*EXAMINET: while if ir therence considered, whether or not citation is in conformance with MPEP 069. Draw line through citation in finct in conformance and not considered, include copy of copy of this form with not communication to applicant. \*Applicant's value catation designation number 0.3 see Kinds Codes of USP10 Petern Documents at <a href="https://www.uspic.gov.com/PEP 09104">https://www.uspic.gov.com/PEP 09104</a> \*Enter Office that issued the document, by the two-letter compared (WIPO Standard ST. 3).

\*For Japanese patient documents, the indication of the year of the reign of the Emporer must precede the serial number of the patient must be "Kinds of document" while the present of the present preceded the serial number of the patient with the present preceded the serial number of the patient with the present preceded the serial number of the patient with the present preceded the serial number of the patient with the present preceded the serial number of the patient with the present preceded the serial number of the patient preceded the patient preceded the serial number of the patient preceded the serial number of the patient preceded the patient patient preceded the patient pre

Examiner

Signature

Translation is attached.

Translation is attached.

Translation of information is required by 37 CFR 197 and 19.8 The information is required to obtain or retain a benefit by the public which is to file (and by the Tiss collection of Information is required to with the collection is estimated to take 2 to complete the full USFT 0.9 process) an application. Confidentially is governed by, 30 LB Cs. [22 and 37 CFR 114 lbs collection is estimated to take 2 to complete the full collection of the co

Date

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/559 925 INFORMATION DISCLOSURE Filing Date May 02, 2006 STATEMENT BY APPLICANT First Named Inventor Oron YACOBY-ZEEVI et al Art I Init 1644 (use as many sheets as necessary) DIBRINO, MARIANNE NMN Examiner Name Attorney Docket Number 30337 Sheet 4 U.S. PATENT DOCUMENTS PCT WO 98/03638 01-29-1998 Freeman et al. 0.6 Nicolson et al. 00 PCT WO 88/01280 02-25-1988 100 PCT WO 01/00643 04-4-2001 Pecker et al. 09-30-1999 Yacoby-Zeevi 101 PCT WO 99/48478 PCT WO 00/03036 01-20-2000 Ben-Artzi et al. 102 05-11-2000 Peretz et al. 103 PCT WO 00/25817 01-23-1992 Nicolson et al 104 PCT WO 92/01003 04-25-2002 Yacoby-Zeevi 105 | PCT WO 02/32283 PCT WO 02/19962 03-14-2002 Ilan et al. 106 Pecker et al. 06-28-2001 107 AU 735116 108 AU 768820 08-8-2004 Ben-Artzi et al. 11-11-1999 Ben-Artzi et al. 109 PCT WO 99/57244 110 PCT WO 99/57153 11-11-1999 Pecker et al. 111 PCT WO 99/11798 03-11-1999 Pecker et al. Examiner Date

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 900. Draw him through distint in fact in conformance and not considered, include copy of one open one of the property of the property of the open of the property of the property of the open of USPTO Patient Documents at tww waysogo.gov or MPEP 901 0.4. "Either Office that issued the document, by the threeter code (WMPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sent number of the patent document. "Knid of document by the appropriate symbols as indicated on the document under WMPO Standard ST.16 if possible "Applicant is to place a check mark here if English language

Signature

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a brandith by the public which is to file (and by the This collection of information is required to both or complete. Brother this public which is to file (and by the This collection of public public which is to file (and by the This collection of public publ

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Lindan sha Danana	out Paduation	n Act of 1995, no persons are required to respond to a colle	ection of i	U.S. Patent and Trademark Office information unless it contains a valid Office	MR contre	of number			
onder the raperw			ection or i	Compl	ete if Kı	nown			
	Su	bstitute for form 1449A/PTO		Application Number	10/559	9,925			
T	NEOD	MATION DISCLOSURE		Filing Date		2, 2006			
				First Named Inventor		YACOBY-ZEEVI et al			
2	STATE	MENT BY APPLICANT		Group Art Unit	1644				
	luse	as many sheets as necessary)		Examiner Name	DIBR	NO, MARIANNE NMN			
	,		Attorney Docket Number	30337					
heet	5	Of	27						
		OTHER PRIOR ART – NON PAT Include name of the author (in CAPITAL LETT							
Examiner	Cite					T <sup>2</sup>			
nitials	No.1	number(s), publisher, city and/or country where published.							
	112	Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene",							
	1	Journal of Biological Chemistry, 270(							
	113	Carlone et al. "Embryonic Modulation of Basic Fibroblast Growth Factor in							
	1	the Rat Uterus", Biology of Reproduct							
_	114	Wight et al. "The Role of Proteoglyca			d				
	1	Proliferation", Current Opinion in Cel	l Biolo	ev. 4: 793-801, 1992.					
	115	Rader et al. "A Phage Display Approa	ch for	Rapid Antibody Humanizat	tion:				
	1	Designed Combinatorial V Gene Libra							
		8910-8915, 1998.			,				
	116	Wordinger et al. "The Immunolocalza	tion of	Basic Fibroblast Growth F	actor				
	110	in the Mouse Uterus During the Initial							
		Growth Factors, 11(3): 175-186, 1994							
	117	Schultz et al. "Growth Factors in Prein			••				
	117	Oxford Review of Reproduction in Bi	iology	15: 43-81 1993 Abstract	,				
	118	Yazaki et al. "The Structure and Expre	eccion d	of the EGE Recentor-1 mR	NΑ				
	110	Isoforms in Rat Tissues", Biochimica	et Rior	shysica Acta 1172: 37-42	1993				
	119	Richardson et al. "Regulation of Basic	Fibro	blact Growth Factor Bindin	g and				
	119	Autivity by Call Donsity and Henoran	Sufate	" I Biological Chemistry	<b>5</b> u				
		Avtivity by Cell Density and Heparan Sufate", J. Biological Chemistry, 274(19): 13534-13540, 1990.							
	120	Hayward et al. "Cellular Mechanisms	of Uer	perinace III Protection in Ro	ıt.				
	120	Traumatic Shock", American Journal							
	121	Sasisekharan et al. "Heparinase Inhibi	to Mag	siology, 275. 1125-1150, 17	1				
	121	Acad.Sci. USA. 91: 1524-1528, 1994							
	122	Whitelock et al. "The Degradation of							
	122	Perlecan and Release of Bound Basic							
		Stromelysin, Collagenase, Plasmin, ar	FIDIOU	and the second second of Piolo	aical				
		Chemistry, 271(17): 10079-10086, 19	na riep	aranases , Journal of Biolo	gicui				
	123	Ishai-Michaeli et al. "Heparanase Act	ivita E	enrected by Platelete					
	123	Neutrophils, and Lymphoma Cells Re	long E.	Active Fibroblest Growth	Factor				
		From Extracellular Matrix", Cell Regi	ulation	1. 832.842 1000	actor				
	104	Godder et al. "Heparanase Activity in	Cultur	od Endethelial Cella" Jour	nol of				
	124	Godder et al. "Heparanase Activity in	Cuitur	ed Endotnenai Cens", Jour	nai of				
	100	Cellular Physiology, 148: 274-280, 19	991.		1				
	125	Kato et al. "Physiological Degradation	n Conv	eris ine Soluble Syndecan-					
		Ectodomain From An Inhibitor to A F	rotent A	Activator of FGF-2", Natur	c				
		Medicine, 4(6): 691-697, 1998.			T				
	126	Jin et al. "Immunochemical Localizat	ion of l	Heparanase in Mouse and I	iuman				
		Melanomas", International Journal of	Cance	r, 45: 1088-1095, 1990.					
Signature	1			Cons	idered				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. \*Applicant's anjuge citation designation number (optional). \*See Kinids Codes of USPTO Patent Occurrent, by the work sustained on the Code of USPTO Patent Occurrent, by the work sustained on the Code of Standard ST 3).

\*For Japanese patent documents, the indication of the year of the regin of the Emperor must precade the sent number of the patent document. \*Year of Code of the Code of Translation is attached.

Transistion is attached.

Transistion is attached in Transistion is required by 3 °CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the Transiscolorism) of indeptication. Confederation is provinced by 3.9 U.S. C. 122 and 37 CFR 1.4 his collection is estimated to take 2 houses to complete, including pathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete his form and/or suggestions for reducing this budner, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

- Lindon the Dec	nomunel Parkunting	Ast of 1995 no persons are read	ired to removed to a call	oction of i		ice: U.S. I	DEPARTMENT OF COMMERC					
Officer the Fag			incu to respond to a con-	cenon or		lete if K						
	Su	ostitute for form 1449A/PTO			Application Number	10/559	9,925					
	INFOD	MATION DISCL	OCUDE		Filing Date	May 0	12, 2006					
					First Named Inventor	Oron	YACOBY-ZEEVI et al					
	STATE	MENT BY APPI	JCANT		Group Art Unit	1644						
	(use	as many sheets as nece:	isary)		Examiner Name	DIBR	INO, MARIANNE NMN					
Sheet	6	Of		27	Attorney Docket Number	30337						
		OTHER PRIOR A	RT – NON PAT	ENT L	ITERATURE DOCUMEN	\TS						
	127	Hoogewerf et al. "CX	C Chemokines C	Connec	tive Tissue Activating Per	tide-						
1		111 and Neutrophil Ac	tivating Peptide-	2 Are l	Heparin/Heparan Sulfate-							
					Chemistry, 270(7): 3268-3	277.						
		1995.P.3269										
	128	Oldberg et al. "Chara	Oldberg et al. "Characterization of A Platelet Endoglycosidase Degrading									
			Heparin-Like Polysaccharides", Biochemistry, 19: 5755-5762, 1980.									
	129				Detection of Malignancy	n						
ŀ	1.27	Urine Samples From					1					
l	1				Cancer, 79(6): 560-564, 19	98						
		Abstract.										
	130		-Inducible Enhan	ncer A	tivity of the First Intron o	fthe						
	150	Bovine β-Casein Gen										
	131	Gottschalk et al. "Sor	natic Gene Thera	ny Pr	esent Situation and Future							
	1.5.	Perspective", Arzneimittelforschung, 48(11): 1111-1120, 1998. Abstract.										
	132	Guriec et al. "CD44 Isoforms With Exon V6 and Mestastasis of Primary										
	1.52											
l		N0M0 Breast Carcinomas", Breast Cancer Res. Treat., 44(3):261-268, 1997.  Abstract.										
	133	Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and										
l	133											
		Function in Tumor Progression and Metastasis", Nature Medicine, 5(7): 793-802, 1999.										
	134		nvolvement of W	ound-	Associated Factors in Rat	3rain						
	1.54	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", J.										
		Clin. Invest., 97(1): 162-171, 1996.										
	135	Zheng et al. "Increme	ent of hF1X Expr	ession	With Endogenous Intron 1	In						
	1.55	Zheng et al. "Increment of hF1X Expression With Endogenous Intron 1 In Vitro", Cell Res., 7(1):21-29, 1997 Abstract.										
	136	Welch et al "Express	sion of Ribozyme	s in Ge	ene Transfer Systems to							
	130	Modulate Target RN	1998.	1								
		Abstract.	i Levelo , cuii	ор		,						
	137		tating Oligonucle	otide I	Delivery: Helping Antisen:	e						
	137	Deliver on Its Promis	e". Proc. Natl. A	cad. Sc	i. USA, 93: 3161-3163, I	996.						
	138				Evolving Technology for							
	1.50				isease", Journal of Americ							
		Cell Surgery, 191(1):										
-	139	Agrawal "Antisense	Oligonucleotides	· Towa	rds Clinical Trials", TIBT	ech.						
	1.57	14: 376-387, 1996.	ogomue.co.iucs		,	,						
-	140	Paiur et al "Covalen	t Protein-Oligoni	cleotic	le Conjugates for Efficien	_						
	140				gate Chem., 8: 935-940, 1							
	141				deoxynucleotide Delivery							
	141	Getting There Is Hall										
1	_	Gennig There is rial		cu,		_						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if no in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number copy. The conformance is supported. The conformance is supported by the conformance is supported. The conformance is supported by the conformance is supported by the conformance is supported by the conformance is conformance. Also did office conformance is conformance in the conformance is conformance. Also did office conformance is conformance in the conformance is conformance in the conformance is conformance. Also did office conformance is conformance in the conformance is conformance in the conformance in the conformance is conformance in the conformance is conformance in the conformance in the conformance in the conformance is conformance in the con

Signature

Intersaum's a standards.

This collection of intersal to septime by 3T CPR 1 97 and 1 98. The information is required to obtain or retain a benefit by the possible which is to file (and by the Time collection of interpolation) in confidentially is governed by 3 till S.C. 122 and 3T CPR 1 1 this collection is estimated to take 2 hours to complete, including pathening, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete the including case and the complete the complete the complete the complete and complete the complete th

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

					U.S. Patent and Trademark Offi information unless it contains a valid C	ce: U.S. L	DEPARTMENT OF COMMERC	
Under the Paperv	vork Reduction	Act of 1995, no persons are	required to respond to a con-	ection of i	Compl	ete if Kr	nown	
	Sub	stitute for form 1449A/PT	о		Application Number	10/559		
	DEOD	A ATTON DIC	CT OCTIDE		Filing Date		2, 2006	
		MATION DIS			First Named Inventor		ACOBY-ZEEVI et al	
!	STATE	MENT BY AP	PLICANT		Group Art Unit	1644		
	(use i	as many sheets as n	ecessary)		Examiner Name	DIBRI	NO, MARIANNE NMN	
Chant	7		Of	27	Attorney Docket Number	30337		
Sheet	+'	OTHER PRIO			ITERATURE DOCUMEN			
	142				Uptake in Primary Human			
	142				Lipids and Depends on th			
			ell Subset", Blood, 9			٠ ١		
	143	Floragen et al. "B	otent and Selective (	Sene Ir	hibition Using Antisense			
	143				ular Biochemistry, 172: 21	3-		
		225, 1997.	otides , molecular ar	id CCII	and Dioenemiony, 172.21	_		
	144	Acki et al "In Vi	vo Transfer Efficienc	cv of A	ntisense Oligonucleotides	Into		
	1,44	the Myocardium	Using HVI-Linosom	e Meth	od", Biochemical and			
	i	Biophysical Rese	arch Communication	is. 231	540-545, 1997.			
	145				ntitative Evaluation of			
	1				Biophysica Acta, 1520: 105	5-114,		
2001.								
	146	Walton et al. "Pre	diction of Antisense	Oligo	nucleotide Binding Affinity	to A		
	1				Bioengineering, 65(1): 1-9			
		1999.		-				
	147	Wang et al. "Isola	ation and Characteriz	zation c	f Pseudomonas Aeruginos	a		
		Genes Inducible	by Respiratory Mucu	ıs Deri	ed From Cystic Fibrosis			
		Patients", Mol. N	licrobiol., 22(5): 100	5-1012	, 1996. Abstract.			
	148	Davies et al. "Re	gulation of the Algin	ate Bio	synthesis Gene AlgC in			
		Pseudomonas Ae	ruginosa During Bio	film D	evelopment in Continuous			
		Culture", Appl. E	nviron. Microbiol., 6	51(3): 8	60-867, 1995. Abstract.			
	149	Azghani et al. "A Beta-Linked Mannan Inhibits Adherence of Pseudomonas Aeruginosa to Human Lung Epithelial Cells", Glycobiology, 5(1): 39-44,						
			ıman Lung Epithelia	l Cells'	', Glycobiology, 5(1): 39-4	4,		
		1995. Abstract.	1995. Abstract.					
	150	Ofek et al. "Bacterial Adhesion to Cells and Tissues", Chapman & Hall, NY,						
		P.114-118, 148-153, 418-423, 420-423, 1994. Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill						
	151	Ghani et al. "Cef	azidime, Gentamicii	n, and I	Giampicin, in Combination	ı, Kılı		
				rugino	sa", Can. J. Microbiol., 43(	11):		
		999-1004, 1997.	Abstract.	n 1				
	152	Gabriel et al. "In	Vitro Adherence of	Pseudo	monas Aeruginosa to Four			
		Intraocular Lense	s", J. Cataract Refra	ct Surg	., 24: 124-129, 1998.	aid.		
	153	Pier "Kationale f	or Development of II	mmunc	therapies That Target Muc Fibrosis Patients", Behrin	otu a Inet		
				ı Cystie	ribiosis ratients", Benrin	g mst.		
	154	IVIIII., 98: 350-36	0, 1997. Abstract.	Antoh -	dies to the Neutral			
	154	Hatano et al. "Bi	ologic Activities of A	Antobo	iles to the incutral-			
		I inoncheses	ide Are Blocked by (	ALICUDIA ALICA C	Thains and Mucoid			
			de (Alginate)", Infec					
1	1	Exopolysacchari	ie (Aigniale), lillec	t. millin	an., 05(1). 21-20.			

\*EXAMINER; Initial if reference considered, whether or not obtains in conformance with MPEP 600. Draw line through citation if not in conformance and not considered include copy of copy of this form with not for communication to applicant." Applicant is evige citation designation number 60m; "See Kinds Codes of USPTO Patent Documents at the accusation," See Kinds Codes of USPTO Patent Documents, the time of the second of the second

Signature

Infrastencia attached.
This collection of Infrastration is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the quality or which is falle (and by the This collection of Infrastration is required by 30 U.S.C. ST. 1.18 in added in the estimated is below 21 work to complete including USFTO by process) an application. Confidentiatily is governed by 30 U.S.C. ST. 1.18 in added in the estimated is below 21 work to complete the formation of the process of the estimated in the complete that form adder suggestions for reducing the budge, and the process of the estimated in the confidential case. Any comment on the amount of time you require to complete this form adder suggestions for reducing the budge, about the sent to the Chief Infrastration Clifford, U.S. Department of commence, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patrices, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Considered

			U.S. Patent and Trademark (	Office: U.S. DEPARTMENT OF COMMER					
Under the Pape	rwork Reduction	n Act of 1995, no persons are required to respond to a collec-	tion of information unless it contains a va	omplete if Known					
	Su	bstitute for form 1449A/PTO	Application Number	10/559.925					
	DEOD	MATION DIGGLOSTINE	Filing Date	May 02, 2006					
		MATION DISCLOSURE	First Named Inventor	Oron YACOBY-ZEEVI et al					
	STATE	MENT BY APPLICANT	Group Art Unit	1644					
(use as many sheets as necessary)			Examiner Name	DIBRINO, MARIANNE NMN					
Sheet	8	Of	27 Attorney Docket Number	r 30337					
		OTHER PRIOR ART - NON PAT	ENT LITERATURE DOCUM	MENTS					
	155	Meluleni et al. "Mucoid Pseudomonas A	Aeruginosa Growing in A Bio	ofilm In					
	1	Vitro Are Killed by Opsonic Antibodies	s to the Mucoid Exopolysacch	naride					
		Capsule But Not by Antibodies Produce	ed During Chtonic Lung Infec	ction in					
		Cystic Fibrosis Patients", J. Immun., 15							
	156	Vernet et al. "Virulence Factors (Aerob							
	1.50	Klebsiella Pneumoniae and Escherichia							
	1	Microbiol. Lett., 130(1): 51-57, 1995. A		,					
	157	Pier et al. "How Mutant CFTR May Co		uginosa					
	157								
	1	Infection in Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 154(4): \$175-							
	150	S182, 1996. Abstract.  Pier et al. "Cystic Fibrosis Transmembrane Conductance Regulator Is An							
	158	Epithelial Cell Receptor for Clearance							
				rioni tile					
	1.50	Lung", Proc. Natl. Acad. Sci. USA, 94( Boucher et al. "Mucoid Pseudomonas A	22). 12000-12093, 1997.						
	159	Characterization of Muc Mutations in C	teruginosa in Cystic Pibrosis:	-6					
		Characterization of Muc Mutations in C	linical isolates and Analysis	65(0)					
		Clearance in A Mouse Model of Respir	atory intection", intect. immi	un., 65(9):					
		3838-3846, 1997. Abstract.							
	160	Boucher et al. "Two Distinct Loci Affee							
		Pseudomonas Aeruginosa in Cystic Fib	rosis Encode Homologs of th	e Serine					
		Protease HtrA", J. Bacteriol., 178(2): 511-523, 1996. Abstract.							
	161	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Pulmonary Clearance of							
	1	Mucoid Pseudomonas Aeruginosa and Inflammation in A Mouse Model of							
		Repeated Respiratory Challenge", Infection and Immunity, 66(1): 280-288,							
		1998.							
	162	Van Heeckeren et al. "Excessive Inflam	ibrosis						
		Mice to Bronchopulmonary Infection With Pseudomonas Aeruginosa", J. Clin.							
		Invest., 100(11): 2810-2815, 1997.							
	163	Cai et al. "Comparison of Sputum Proc		Fibrosis",					
		Pediatr. Pulmonol., 22(6): 402-407, 199							
	164	Hatch et al. "Alginate Lyase Promotes	Diffusion of Aminoglycoside	s Through					
		the Extracellular Polysaccharide of Mu		sa",					
		Antimicrob. Agents. Chemother., 42(4)	): 974-977, 1998. Abstract.						
	165	Speert et al. "Modulation of Macrophage	ge Function for Defense of the	e Lung					
		Against Pseudomonas Aeruginosa", Be	hring Inst. Mitt., 98: 274-282	2, 1997.					
		Abstract.							
	166	Pina et al. "The Role of Fluoroquinolor	nes in the Promotion of Algin	ate					
		Synthesis and Antibiotic Resistance in	Pseudomonas Aeruginosa", C	Curr.					
		Microbiol., 35(2): 103-108, 1997. Abst							
_									

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP exp. Draw into though citation if not nonformance and not considered, include copy of this form with inext communication to applicant. Applicant's seque cetains resignation under (colorary) See Kinds Cober of USPTO Patient Documents at travallationation of the property of the Communication o

Signature

Inansation is attached in This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by se public which is to file (and by the This collection of information is required by 3.0 L 1.22 and 3.7 CFR 1.41 this collection is estimated to take 2 hours to complete application. Confidentiality is governed by 3.0 L 5.2. T.22 and 3.7 CFR 1.41 this collection is estimated to take 2 hours to complete application. Supplied to the complete application of the complete applicati

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/559.925 May 02, 2006 Filing Date INFORMATION DISCLOSURE Oron YACOBY-ZEEVI et al First Named Inventor STATEMENT BY APPLICANT Group Art Unit 1644 DIBRINO, MARIANNE NMN Examiner Name (use as many sheets as necessary) Attorney Docket Number 27 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Mengistu et al. "Continuous Culture Studies on the Synthesis of Capsular 167 Polysaccharide by Klebsiella Pneumoniae K1", J. Appl. Bacteriol., 76(5): 424-430, 1994, Abstract. Hsuch et al. "Invasive Streptococci Pneumoniae Infection Associated With 168 Rapidly Fatal Outcome in Taiwan", J. Formos Med. Assoc., 95(5): 364-371, 1996, Abstract. Moses et al. "Relative Contributions of Hyaluronic Capsule and M Protein to 169 Virulence in A Mucoid Strain of the Group A Streptococcus", Infect. Immun., 65(1): 64-71, 1997. Scott et al. "Visualization of An Extracellular Mucoid Laver of Treponema 170 Denticola ATCC 35405 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral Microbiol. Immunol., 12(2): 121-125, 1997. Abstract. Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression in Septricemia and Septic Arthritis", Infect. Immun., 65(10): 4216-21, 1997. Abstract. Wessels et al. "Effects on Virulence of Mutations in A Locus Essential for Hyaluronic Acid Capsule Expression in Group A Streptococci", Infect. Immun., 62(2): 433-441, 1994. Abstract. Farndale et al. "A Direct Spectrophotometric Microassay for Sulfated Glycosaminoglycans in Cartilage Cultures", Connective Tissue Research, 9: 247-248, 1982, Pasquier et al. "Implication of Neutral Polysaccharides Associated to 174 Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa", FEMS Microbiol. Lett., 147(2): 195-202, 1997. Abstract. Marty et al. "Influence of Nutrient Media on the Chemical Composition of the Expolysaccharide From Mucoid and Non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, 77(1-3): 35-44, 1992. Abstract. 176 Jorba et al. "Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars", Rev. Esp. Fisiol., 36(2): 155-161, 1980. Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Environ. Microbiol., 67(1): 33-41, 2001, Abstract, Bhaskar et al. "Dysregulation of Proteoglycan Production by Intraheptic 178 Biliary Epithelial Cells Bearing Defective (Delta-f508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatology, 27(1): 7-14, 1998. Abstract.

\*EXAMNER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. Applicant's reque citation designation number (optionals). "See Krists Codes of USPTO Platent Documents at www.nuslios.gov or MPEP 901.04." Enter Office that issued the document, by the two-testin code (WPP 50 Standard ST.3.) \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of docume by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English tanguage Translation is attached.

Signature

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the URST Opposition or incrimental is required by 3 or V.F. 1. M and 1. Mo. In an information is required to obtain or resum a serentity time public which is to till (and by the USPTO in process) an application. Confidentially is governed by 3.5 U.S. C. 122 and 3 T.G.F. 1. His collection is estimated to take 2 not use to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this chair market support some control of time you require to complete this chair market support some control of time you require to complete this chair market support some control of time you require to complete this chair market support some control of time you require to complete this chair and or trademark Office, U.S. Oppathering of complete this chair. As 2 shared and Trademark Office, U.S. Oppathering of complete this chair. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Application Number 10/559,925 INFORMATION DISCLOSURE Filing Date May 02, 2006 Oron YACOBY-ZEEVI et al First Named Inventor STATEMENT BY APPLICANT Group Art Unit 1644 Examiner Name DIBRINO, MARIANNE NMN (use as many sheets as necessary) Of Attorney Docket Number Sheet 10 27 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS 179 Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IMR-90) Maintained in A Low Concentration of Serum", Biochem, J., 207(3): 369-379. Abstract. 180 Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mouse Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract. 181 Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9): 698-702, 1975. Rahmoune et al. "Chrondroitin Sulfate in Sputum From Patients With Cystic 182 Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991. Abstract. 183 Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Tissue", Eur. J. Clin. Microbiol., 6(5): 591-593, 1987. Abstract. 184 Allison et al. "Polysaccharide Production in Pseudomonas Cepacia", J. Basic. Microbiol., 34(1): 3-10, 1994. Abstract. Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response 185 to Lung Infection in Patients With Cystic Fibrosis", J. Clin. Microbiol., 26(12): 2505-2509, 1988. Abstract. 186 Macone et al. "Mucoid Escherichia Coli in Cystic Fibrosis", The New England Journal of Medicine, 304(24): 1445-1449, 1981. Abstract. Tatnell et al. "Characterisation of Alginates From Mucoid Strains of 187 Pseudomonas Aeruginosa", Biochemical Society Transactions, 24: 404S, 1996 188 Tatnell et al. "Chemical Analysis of Alginates From Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions, 22: 310S, 1994 189 Tatnell et al. "Colonisation of Cystic Fibrosis Patients by Non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate From Mucoid Variants", Biochemical Society Transactions, 24: 406S, 1996. Drigues et al. "Comparative Studies of Lipopolysaccharide and 190 Exopolysaccharide From A Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology, 162(2): 504-509, 1985, Abstract, 191 Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides", Biotech. Adv., 12: 393-448, 1994. Anatolii "Hvaluronic Capsule as One of the Factors of Hemolytic 192 Streptococcus Pathogenicity", Chem. Abstracts 86(17): 339, 1977.

"EXAMINET, initial ir reference considered, whether or not clustion is in conformance with MPEP 600. Draw time through clustion in from (inconformance and not considered, include, copy of copy of this from with next communication to applicant. Applicant's angine cluston designation under (original). See Kinds Codes of USPTO Patient Documents at <a href="https://www.usot.org/">https://www.usot.org/</a> or MPEP 901.04. \*\* Enter Office that issued the document, by the two-letter code (VIPPO Standard ST.3). \*\* For Japanese paint document, the findication of the year of the regin of the Emperor must proceed the senal number of the patent document. \*\* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*\*Applicant is to place a check mark here if English language Translation as stated.\*\*

Abstr 118714 in Zh. Mikrobiol. Epidemiol. Immunobiol., 2; 22-27, 1977.

Signature

This addession of immunition is required by 37 CFR, 197 and 1.98. The information is required to obtain or region a benefit by the public which is to file (and by the USPTO 0.50 process) as application. Confedentiative is powered by 35 U.S. C. 22 and 37 CFR. 14 Nits collection is estimated to take 2 not complete. Including pathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your exquire to complete this formation supervisions for reducing this busders, should be seen to the Child Information Officer, USP and the Complete the Complete

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO Application Number 10/559,925 May 02, 2006 INFORMATION DISCLOSURE Filing Date First Named Inventor Oron YACOBY-ZEEVI et al STATEMENT BY APPLICANT Group Art Unit 1644 Examiner Name DIBRINO MARIANNE NMN (use as many sheets as necessary) Attorney Docket Number | 30337 Of 27 11 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS 193 Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980. Li et al. "Immunochemical Localization of Heparanase in Mouse and 194 Human Melanomas", Int. J. Cancer, 45: 1088-1095, 1990. Soule et al. "Isolation and Characterization of A Spontaneously 195 Immortalized Human Breast Epithelial Cell Line, MCF-101", Cancer Res., 50: 6075-6086, 1990. Abstract. Miller et al. "Xenograft Model of Progressive Human Proliferative Breast 196 Disease", J. Nat. Cancer Inst., 85: 1725-1732, 1993. Abstract. Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion 197 and Metatastic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613, 1983. Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular 198 Heparanase", Molecular Biology/Biochemistry, Proceedings of the

American Association for Cancer Research, 37: 495, 1996. Suppl. IDS in

Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine

- B-Lymphocytes", International Journal of Cancer, 47(1): 92-98, 1991. Cordon-Cardo et al. "Expression of Basic Fibroblast Growth Factor in

Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990.

Hillier et al. "The WashU-Merck EST Project", No. N30824, Database

Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997. Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In

Pediatric Pulmonology, 22: 161-166, 1996.

3067-3074, 1980. Abstract.

Vitro Using Combined Treatment With Nacystelyn and RhDNase",

Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not

Sulftate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995.

GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Hillier et al. "The WashU-Merck EST Project", No. N30845, Databse

GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Konstan et al. "Current Understanding of the Inflammatory Process in

Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13):

22716:

Abstract.

Abstract.

199

200

201

202

203

204

205

206

Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 60s. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or white Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or white Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or white Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or white Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or white Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or white Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or white Set Fill of Uspto.gov</a> or white Set Fill of Uspto Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or white Set Fill of Uspto.gov</a> or <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>4</sup> Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Intornation Officer, U.S. Patent and Tradhomark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, V.A. 2231-1450. ON ON TSEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known Substitute for form 1449A/PTO 10/559.925 Application Number May 02, 2006 INFORMATION DISCLOSURE Filing Date Oron YACOBY-ZEEVI et al First Named Inventor STATEMENT BY APPLICANT Group Art Unit 1644 Examiner Name DIBRINO, MARIANNE NMN (use as many sheets as necessary) 12 Of Attorney Docket Number | 30337 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS 207 Cheng et al. "Increased Sulfaton of Glycoconjugates NY Cultured Nasal Epithelial Cells From Patients With Cystic Fibrosis", J. Clin. Invest., 84(1): 68-72, 1989, Abstract, 208 Boat et al. "Epithelial Cell Dysfunction in Cystic Fibrosis: Implications for Airways Disease", Acta Paediatr, Scand, Suppl., 363: 25-29, 1989. Schwatz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the 209 Lower Respiratory Tract", J. Clin. Invest., 100(1): 68-73, 1997. Abstract. 210 Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomonas Aeruginosa Requires Facilitated Transport of D-Glucose by Macrophages", J. Immunol., 154(7): 3420-3428, 1995. Abstract. Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe in Th2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice", APMIS, 105(11): 838-842, 1997. Abstract. Zahm et al. "Early Alterations in Airway Mucociliary Clearance and Inflamation of the Lamina Propria in CF Mice", Am. J. Physiol., 272(3 Pt 1): C853-C859, 1997, Abstract. Thompson et al. "Identification of Chondroitin Sulfate E in Human Lung Mast Cells", J. Immunol., 140(8): 2708-2713, 1988. Abstract. Giuffre et al. "Monocyte Adhesion to Activated Aortic Endothelium: Role 214 of L-Selectin and Heparan Sulfate Proteoglycans", J. Cell Biol., 136(4): 945-956, 1997. Abstract. 215 Margolies et al. "Identification of A Major Heparin-Precitable Protein in Human Serum and Its Relationship to Cystic Fibrosis", Pediatr. Res., 16(3): 181-186, 1982. Abstract. 216 Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of Borrelia Burgdorferi to Cultured Endiothelial and Brain Cells", Infect. Immun., 66(3): 994-999, 1998, Abstract. Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", J. Vet. Med. Sci., 59(8): 727-728, 1997. Abstract. Krusat et al. "Heparin-Dependent Attachment of Respiratory Syncytial 218 Virus (RSV) to Host Cells", Arch. Virol., 142(6): 1247-1254, 1997. Abstract. 219 Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by Theileria Sergenti Merozoites", Int. J. Parasitol., 27(5): 535-539, 1997. Abstract. 220 Shakibaei et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the Low Density Lipoprotein Receptor-Related Protein (LRP) and

\*EXAMINER: initial if reference considered, whether or not otation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. "Applicant's insight entities designation number (optional)." See Kinds Codes of USPTO Patent Documents at www.nusglo.gozy or MPEP 951.04. "Enter Office that issued the document, by the wo-fetter code (WPD Standard ST.3.). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must proceed the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Heparan Sulfate Proteoglycans", J. Exp. Med., 184(5): 1699-1711, 1996.

Abstract.

Signature

Inansaron is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fis (and by the This collection of information) is required by 30 LIS C. 22 and 37 CFR 1.4 is be collected in the settlement of the SE 2 but to complete insoling the property of the SE 2 but to the SE 2 but

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO 10/559 925 Application Number May 02, 2006 INFORMATION DISCLOSURE Filing Date First Named Inventor Oron YACOBY-ZEEVI et al STATEMENT BY APPLICANT 1644 Group Art Unit DIBRINO, MARIANNE NMN Examiner Name (use as many sheets as necessary) Of 27 Attorney Docket Number | 30337 13 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS 221 Jusa et al. "Effect of Heparinon Infection of Cells by Porcine Reproductive and Respiratov Syndrome Virus", Am. J. Vet. Res., 58(5): 488-491, 1997. Abstract. Chen et al. "Dengue Virus Infectivity Depends on Envelope Protein Bin to Target Cell Heparan Sulfate", Nature Medicine, 3(8): 866-871, 1997. Abstract. Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite Protein and Thrombospondin Is Mediated by Its Glycosminoglycan-Binding Region and Not by CSVTCG", J. Biol. Chem., 272(31): 19205-19213, 1997. Abstract. 224 Robert et al. "Chondroitin-4-Sulphate (Proeoglycan), A Receptor for Plasmodium Falciparum-Infected Erthrocyte Adherence on Brain Microvascular Endothelial Cells", Res. Immunol., 146(6): 383-393, 1995.

Berkow "The Merck Manual", Merck Research Laboratories, P.201, 204,

Frederiksen et al. "Changing Epidemiology of Pseudomonas Aeruginosa

Infection in Danish Cystic Fibrosis Patients (1974-1995)", Pediatr.

Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part 11. Use of

1308, 177-179, 1016-1017, 194-197, 885, 601, 1997.

23(5): 330-335, 1997, Abstract.

Pulmonol., 28(3): 159-166, 1999. Abstract.

Therapies", Pediatr. Pulmonol., 28(4): 248-54, 1999. Abstract.
Frederiksen et al. "Antibiotic Treatment of Initial Colonization with
Pseudomonas Aeruginosa Postpones Chronic Infection and Prevents
Deterioration of Pulmonary Function in Cystic Fibrosis", Pediatr. Pulmonol.

226

228

	229	Ramsey et al. "Intermittent Administraton of Inhaled Tobramycin in Patients	
		With Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group",	
		New England Journal of Medicine, 340(1): 23-30, 1999. Abstract.	
	23 i	Tang et al. "Contribution of Specific Pseudomonas Aeruginosa Virulence	
		Factors to Pathogenesis of Pneumonia in A Neonatal Mouse Model of	
		Infection", Infect. Immun., 64(1): 37-43, 1996. Abstract.	
	231	Bennett et al. "Effect of Uridine 5'-Triphosphate Plus Amiloride on	
		Mucociliary Clearance in Adult Cystic Fibrosis", Am. J. Respir. Crit. Care	
		Med., 153(6 Pt.1): 1796-1801, 1996. Abstract.	
	232	Armstrong et al. "Lower Airway Inflammation in Infants and Young	
		Children With Cystic Fibrosis", Am. J. Respir. Crit. Care Med., 156(4 Pt.1):	
		1197-1204, 1997. Abstract.	
	233	Naparstek et al. "Activated T Lymphocytes Produce A Matrix-Degrading	
		Heparan Sulphate Endoglycosidase", Nature, 310(5974): 241-244, 1984.	
		Abstract.	
Signature		Considered	

EXAMNER: Initial if retremes considered, whether or not station is in conformance with MPEP 000. Draw line through claison in find in conformance and not considered. Include copy of one of one of the form with next communication to appeared. \*Applicant\* - design can be explained in the conformance and not of USPTO retained Documents at given explained. \*See Kinds Codes of USPTO Posterio Documents at given explained and the second of the communication to appear of the period of the second of the document, by the Vev-letter code (WPO Standard ST.3).

\*\*Enter Office that issued the document, plus individual communication and the second of th

This coincision of information is required by 37 CPR, 197 and 1.98. The information is required to obtain or retain a benefit by the gobble which is to file (and by the USPTO to process) an application. Confidentially is geometred by 38 U.S. C. 122 and 37 CPR, 11 A. this collection is estimated to take 2 hot complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comment on the amount of time your require to complete this includes for reducing the subtract, such days are ent to the Chef Information Officiar. OF, Patient and Trademan's Officiar.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

				U.S. Patent and Trademark Office	ce: U.S. DEPARTMENT OF COMMERCE				
Under the Paper	work Reduction	n Act of 1995, no persons are required to respond to a coll	ection of		olete if Known				
	Su	bstitute for form 1449A/PTO		Application Number	10/559.925				
	INFOD	MATION DICCLOSUDE		Filing Date	May 02, 2006				
		MATION DISCLOSURE		First Named Inventor	Oron YACOBY-ZEEVI et al				
	STATE	MENT BY APPLICANT		Group Art Unit	1644				
	(use	as many sheets as necessary)	Examiner Name	DIBRINO, MARIANNE NMN					
Sheet	14	Of	27	Attorney Docket Number	30337				
		OTHER PRIOR ART - NON PAT							
	234	Weller "Implications of Early Inflama	tion ar	d Infection in Cystic Fibros	sis: A				
		Review of New and Potential Interver	tions"	, Pediatric Pulmonology, 24	k:				
		143-146, 1997.							
	235	Rubin "Emerging Therapies for Cystic	c Fibro	sis Lung Disease", Chest, 1	15:				
		1120-1126, 1999.	·						
	236	Ducy et al. "The Osteoblast: A Sophis	ticated	Fibroblast Under Central					
İ		Surveillance", Science, 289: 1501-1504, 2000.							
	237	Reddi "Role of Morphogenetic Protei	ns in S	keletal Tissue Engineering	and				
	1	Regeneration", Nature Biotechnology, 16: 247-252, 1998.							
	238	Elkin et al. "Heparanase as Mediator	of Ang	iogenesis: Mode of Action"	, The				
		FASEB Journal, 15: 1661-1663, 2001							
	239	Elkin et al. "Henaranase as Mediator			, The				
		FASEB Journal, Published Online, 10							
	240	Finkel "Potential Target Found for Ar	ntimeta	stasis Drugs", Science, 285	: 33-				
		34, 1999.							
	241	Webster et al. "FGFR Activation in S	keletal	Disorders: Too Much of A	Good				
		Thing", TIG, 13(5): 178-182, 1997.							
	242	Shimazu et al. "Syndecan-3 and the C	ontrol	of Chondrocyte Proliferation	on				
Į.		During Endochondral Ossification", E	Exp. Co	ell. Res., 229(1): 126-136, 1	996.				
		Abstract.							
	243	Blanquaert et al. "CMDBS, Functiona							
		as Osseous Cicatrizing Agents", Ann.	4.						
		Abstract.							
	244	Blanquaert et al. "Heparan-Like Mole							
		Defects", Bone, 17(6): 499-506, 1995							
	245	Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin							
		on Trabecular Bone In Vivo", Blood,							
	246	Hoffman et al. "Human Bone Morpho	ogenic	Protein 2 Contains A Hepar	rin-				
		Binding Site Which Modifies Its Biol	ogical	Activity", Eur. J. Biochem.	,				
		237(1): 295-302, 1996. Abstract.							
	247	Imai et al. "Osteoblast Recruitment ar							
		Matrix-Associated Heparin-Binding			-				
		GAM)", J. Cell. Biol. 143(4): 1113-1	128, 19	998. [Abstract]					
	248	Loredo et al. "Regulation of Glycosar	ninogl	ycan Metabolism by Bone					
		Morphogenetic Protein-2 in Equine C	Cartilag	e Explant Cultures", Am. J.	. Vet.				
		Res., 57(4): 554-559, 1996.							
	249	Kiberstis et al. "Bone Health in the B	alance'	', Science, 289: 1497, 2000					
	250	Service "Tissue Engineers Build New	Bone'	", Science, 289: 1498-1500,	2000.				
					2.1				

"EXAMINET: Initial if reference considered, whether or not cisation is in conformance with MPEP 690. Draw time through clastion if not in conformance and not considered, include copy of copy of this form with near communication to applicant. "Applicant "a supplicant location number (solication number (solication)." See Kinds Codes of USPTO Paster Documents at <a href="https://www.insch.gov/not/methods/not/metho

Signature

This solution of information is required by 37 CPR 1.07 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the UPPTO by moses) an application. Confidentially is governed by 38 U.S. C. 122 and 37 CPR 1.14 this collection is estimated to lake 2 hours to complete, including subsering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete the information officer, UPS 2.58 but 4.00. Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Petaring F.O. Box 1450, Alexandris, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pape	erwork Reduction	Act of 1995, no persons are required to respond to a collection of	information unless it contains a valid C	OMB control number.							
	6	bstitute for form 1449A/PTO	Complete if Known								
	30	ballate for form 1449/0F TO	Application Number	10/559,925							
	INFOR	MATION DISCLOSURE	Filing Date	May 02, 2006							
	STATE	MENT BY APPLICANT	First Named Inventor	Oron YACOBY-ZEEVI et al							
	SIAIL	MENT BI ATTECANT	Group Art Unit Examiner Name	DIBRINO, MARIANNE NMN							
	(use	as many sheets as necessary)									
Sheet	15	Of 27	Attorney Docket Number	30337							
		OTHER PRIOR ART - NON PATENT L	ITERATURE DOCUMEN	iTS							
	251	Stracke et al. "Autotaxin, Tumor Motility-Stimulating									
		Exophosphodiesterase", Advan. Enzyme Reg	gul., 37: 135-144, 1997.								
		Introduction.									
	252	Bost et al. "Antibodies Against A Peptide Sequence Within the HIV									
	1	Envelope Protein Crossreacts With Human I	nterleukin-2", 1mmunol. 1n	vest.,							
		17: 577-586, 1988.									
	253	Bendayan "Possibilities of False Immunocyte	ochemical Results Generate	ed by							
		the Use of Monoclonal Antibodies: The Example 1	mple of the Anti-Proinsulin								
		Antibody", J. Histochem. Cytochem. 43: 881	1-886, 1995								
	254	Bar-Ner et al. "Inhibition of Heparanase-Me	diated Degradation of	`							
		Extracellular Matrix Heparan Sulphate by No	on-Anticoagulant Heparin								
		Species", Blood, 70(2): 551-557, 1987.									
	255	Savitsky et al. "Ataxia-Telangiectasia: Struct	tural Diversity of Untransla	ited							
	i	Sequences Suggests Complex Post-Transcrip	otional Regulation of ATM	Gene							
		Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.									
	256	Shieh et al. "Cell Surface Receptors for Herpes Simplex Virus Are Heparan									
		Sulfate Proteoglycan Proteoglycans", J. Cell	. Biol., 116(5): 1273-1281,	1992.							
	257	Lider et al. "A Disaccharide That Inhibits Tu	mor Necrosis Factor ? Is F	formed							
	1	From the Extracellular Matrix by the Enzym	e Heparanase", Proc. Natl.	Acad.							
		Sci. USA, 92: 5037-5041, 1995.									
	258	Spivak-Kroizman et al. "Heparin-Induced O	ligomerization of FGF Mol	ecules							
		Is Responsible For FGF Receptor Dimerizat	ion, Activation, and Cell								
		Proliferation", Cell, 79: 1015-1024, 1994.									
	259	Vlodavsky et al. "Endothelial Cell-Derived I	ctor:								
		Synthesis and Deposition Into Subendothelia	roc.								
		Natl. Acad. Sci. USA, 84: 2292-2296, 1987.	A STATE OF THE STATE OF								
	260	Vlodavsky et al. "Involvement of the ExtraC	Cellular Matrix, Heparin Su	lfate							
		Proteoglycans, and Heparin Sulfate Degradi	ng Enzymes in Angiogenes	is and							
		Metastis", Tumor Angeogenesis, P.125-140,	, 1997.								
	261	Hillier et al. "The WashU-Merck EST Proje	ct" GenBank Entry N32056	5,							
		1996. Claims: 9, 10									
	262	Adams et al. "Initial Assesment of Human C	ene Diversity and Express	ion							
		Patterns Based Upon 83 Million Nucleotides	s of cDNA Sequence", Nati	ure,							
		377(6547): 3-174, 1995. GenBank Entry AA	\304653, 1997. Claims. 30	9.							
	263	Yagel et al. "Normal Nonmetastatic Human	Trophoblast Cells Share In	Vitro							
	1222	Invasive Properties of Malignant Cells", J. C	Cellular Physiology, 136: 4:	55-							
	1	462, 1988.									
	264	Kizaki et al. "Cloning and Localization of H	leparanase in Bovine Placer	nta",							
	201	Placenta, 24: 424-430, 2003.	Action and the Asset								
				- 7 - 1							

\*EXAMINER: Initial if reference considered, whether or not claiston is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of copy of this form with next communication to applicant. \*Applicant's integer catation designation number opening. \*See Initial Codes of USPTO Patent Documents at www.usels.ogy or WPEP 901.04. \*Einst Office that issued catation designation number opening. \*See Initial Codes of USPTO Patent Documents at www.usels.ogy or WPEP 901.04. \*Einst Office that issued catation designation number of the patent mumber of the patent mumber of the patent marked that is a community of the patent marked that the community of the patent of the patent marked that the community of the patent marked that the community of the patent marked that the patent marked that the community of the patent marked that the community of the patent marked that the community of the patent marked that the patent marked that the community of the patent marked that the patent mark

Signature

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required by 3.01 CFR 1.97 and 9.7 CFR 1.18 incl collection is esternated to face 2 hours to complete incubing upserting, and submitting to the complete incubing properties, and submitting to complete incubing the complete incubing and submitting to the complete incubing and submitting to complete incubing and submitted in the complete incubing and submitted incubing and submitted in the complete incubing and submitted in the complete incubing and submitted in the complete incubing and s

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Linder the Pane	muork Reduction	Act of 1995, no persons are required to respond to a coll	ection of	information unless it contains a valid ()	MB control number	
Onder the Pape			ection or	Complete if Known		
	Sul	bstitute for form 1449A/PTO		Application Number	10/559,925	
	INFOR	MATION DISCLOSURE		Filing Date	May 02, 2006	
				First Named Inventor	Oron YACOBY-ZEEVI et al	
	STATE	MENT BY APPLICANT		Group Art Unit	1644	
(use as many sheets as necessary)			Examiner Name	DIBRINO, MARIANNE NMN		
Sheet	16	Of	27	Attorney Docket Number	30337	
		OTHER PRIOR ART - NON PAT	ENT L	ITERATURE DOCUMEN	TS	
	265	Dempsey et al. "Heparanase Expression				
	1	Vascular Damage", Glycobiology, 100				
	1	Col.1 - P.471, Col.1, P.472, Col.1, § 4			'	
	266	Haimov-Kochman et al. "Localization				
	200	Pathological Human Placenta", Molec			66-	
		573, 2002.	uiui II	aman reproduction, o(o). 5	••	
	267	Kizaki et al. "Expression of Heparana:	D	IA in Bassina Blacanta Dur	ina	
	207	Gestation", Reproduction, 121: 573-51			mg	
	260	Edwards et al. "Some Properties and A				
	268	Antibodies", Biochem, Journal, 200: 1				
	260					
	269	Zhou et al. "HFE Gene Knockout Pro-				
	_	Hemochromatosis", PNAS, 95(5): 249				
	270	Menezo et al. "Mouse and Bovine Mo			ve	
		BioMedicine Online 2002, 4(2): 170-				
	271	Bean et al. "Fertilization In Vitro Incre	eases N	Ion-Disjunction During Ear	ly	
		Cleavage Divisions in A Mouse Mode	el Syste	m", Human Reproduction,		
		17(9): 2362-2367, 2002. Abstract.				
	272	Brinster et al. "Restoration of Fertility				
	- 1	Requires Effective Recipient Preparat	ion", B	iology of Reproduction 69:	412-	
		420, 2003. Abstract.				
	273	Liu et al. "Live Offspring by In Vitro				
		Cryopreserved Primordial Mouse Foll				
		Transplantation and In Vitro Maturati	on", Bi	ology of Reproduction, 64:	171-	
	- 1	178, 2001. Abstract.				
	274	Kawase et al. "Effect of Partial Incision	n of th	e Zona Pellucida by Piezo-		
		Micromanipulator for In Vitro Fertiliz				
		Spermatozoa on the Developmental R	ate of	Embryos Transferred at the	2-	
		Cell Stage", Biology of Reproduction,	, 66: 38	310385, 2002. Abstract.		
	275	Pfaff et al. "Cryobiology of Rat Embr	vos I: I	Determination of Zygote		
		Membrane Permeability Coefficients	for Wa	ter and Cryoprotectants, Th	eir	
		Activation Energies, and the Develop	ment o	f Improved Cryopreservation	on l	
		Methods", Biology of Reproduction,	63: 129	94-1302, 2000, Abstract.		
	276	Yesildaglar et al. "The Mouse as A M	odel to	Study Adhesion Formation	1	
	2.0	Following Endoscopic Surgery: A Pre	limina	ry Report". Human	1	
		Reproduction, 14(1): 55-59, 1999. Ab		-,,, ,		
	277	Ejima et al. "Induction of Apoptosis in	n Place	ntas of Pregnant Mice Evo	osed	
	2//	to Lipopolysaccharides: Possible Invo	lveme	nt of Fas/Fas Ligand System	n"	
		Biology of Reproduction, 62: 178-185			",	
	_	Diology of reproduction, 02. 178-18.	, 2000	. / 1030000		

"EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant." Applicant's induce citation designation under objection of the conformance and of USPTO Patent Occurrent at www.psignage.or of MPEP 001 At. "felant offices that assessed her document, by the viscolar content of the conformance and offices of the conformance of the

Signature

Transation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fire (and by the This collection of information is required to proceed by 38 U.S.C. 122 and 37 CFR 1.14 this collection is estimated to take 2 hours become to which of USFT to proceed by 38 U.S.C. 122 and 37 CFR 1.14 this collection is estimated to take 2 hours become to which on which of the control of the

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Papervork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a yall dOME counted number.

Ones and Capture	Substitute for form 1449A/PTO		Complete if Known		
	Sui	ostitute for form 1449AVP TO	Application Number	10/559,925	
T	NFOR	MATION DISCLOSURE	Filing Date	May 02, 2006	
_		MENT BY APPLICANT	First Named Inventor	Oron YACOBY-ZEEVI et al	
				1644	
	(use	as many sheets as necessary)	Examiner Name	DIBRINO, MARIANNE NMN	
Sheet	17	Of 27	Attorney Docket Number	30337	
		OTHER PRIOR ART – NON PATENT L	ITERATURE DOCUMEN	ITS	
	278	Prahalada et al. "Diethylstilbestrol-Induced C Using the Neonatal Mouse Model", Biology 1988. Abstract.	of Reproduction, 38: 935-9		
	279	Newbold et al. "Exposure to Diethylstilbestry Permanently Alters the Ovary and Oviduct", 735-744, 1983. Abstract.	Biology of Reproduction,		
	280	Jin et al. "Molecular Cloning and Expression Proceedings American Association for Cano 1992, 33: 57, 1992. Abstract.	er Research Annual Meetin	ıg,	
	281	Colman "Effects of Amino Acid Sequence C Interactions", Research in Immunology, 145	(1): 33-36. 1994.	en	
	282	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin- Induced Hyperglycenia", Nature Medicine, 6(5): 568-572, 2000.			
	283	Benjamin et al. "A Plasticity Window for Bl Defined by Pericyte Coverage of the Preform Regulated by PDGF-B and VEGF", Develop	ned Endothelial Network ar oment, 125: 1591-1598, 199	nd 1s 98.	
	284	Vukicevic et al. "Induction of Nephrrogenic Protein 1 (Bone Morphogenetic Protein 7)", 9021-9026, 1996.	Mesenchyme by Osteogen Proc. Natl. Acad. Sci. USA	ic 1, 93:	
	285	Massague "The TGF-BETA Family of Grov Cell. 49: 437-438, 1987.			
	286	Pilbeam et al. "Comparison of the Effects of Human Parathyroid Hormone-Related Pepti Bone Resorption and Formation in Organ Co	de (hPTHrP) of Malignancy ulture", Bone, 14: 717-720,	y on	
	287	Skolnick et al. "From Genes to Protein Struc Applications of Computational Approaches Biotechnology, 18; 34-39, 2000.	cture and Function: Novel in the Genomic Era", Trend	ds in	
	288	Bork "Powers and Pitfalls in Sequence Anal Research, 10: 398-400, 2000.			
	288	Doerks et al. "Protein Annotation: Detective Trends in Genetics, 14(6): 248-250, 1998, S	uppl. IDS in 22716;		
	291	Smith et al. "The Challenges of Genome See Is in the Details", Nature Biotechnology, 15	quence Annotation or 'The 5: 1222-1223, 1997.		
	291	Brenner "Errors in Genome Annotation", Tr	rends in Genetics, 15(4): 13	2-133,	
	292	Bork "Go Hunting in Sequence Databases B Trends in Genetics, 12(10): 425-427, 1996.			
	293	Bowie et al. "Deciphering the Message in P Amino Acid Substitutions", Science, 247: 1	rotein Sequences: Toleranc 306-1310, 1990.	e to	
Signature	+-		Con	sidered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through station if not in conformance and not considered, include copy of copy of this form with next communication to applicant. \*Applicants unique citation designation number (pottors) \*2 see Rinds Code of USEPTO Platent Occuments at work upsign. 2007 of MPEP 100 to 1.4. "Eigns of Titles that issued the local consideration of the Performance of the Section Code of the Sec

Translation is attached.
The scaleding of Translation is required by 37 CFF, 197 and 1.98. The intermutation is required to obtain or retain a benefit by the public which is to file (and by the Transcolleding of Intermutation) is required to obtain or retain a benefit by the scale confidence in the Complete Intermutation is required to the complete in the Complete Intermutation is required to the complete in the Complete Intermutation is required to the Complete Intermutation is required to the Complete Intermutation of the Complete Intermu

Approved for use through 06/30/2006. OMB 0651-0031

			U.S. Patent and Trademark Offi	ce: U.S. DEPARTMENT OF COMME		
Under the Pape	erwork Reduction	n Act of 1995, no persons are required to respond to a collection of	f information unless it contains a valid OMB control number.  Complete if Known			
	Su	bstitute for form 1449A/PTO	Application Number	10/559.925		
		T. MICH. DIGGE COURT	Filing Date	May 02, 2006		
		MATION DISCLOSURE	First Named Inventor	Oron YACOBY-ZEEVI et al		
	STATE	MENT BY APPLICANT	Group Art Unit	1644		
			Examiner Name	DIBRINO, MARIANNE NMN		
		as many sheets as necessary)				
Sheet	18	Of 27	Attorney Docket Number	30337		
		OTHER PRIOR ART – NON PATENT L	ITERATURE DOCUMEN	TS		
	294	Bendig et al. "Humanization of Rodent Mone				
		Grafting", Methods in Enzymology, 8: 83-9:				
	295	Goshen et al. "Purification and Characterizat		e and		
		Its Expression by Cultured Cytotrophoblasts	', Molecular Human			
		Reproduction, 2(9): 679-684, 1996.				
	296	Coligan et al. "Current Protocols in Immunol	logy", Immunology - Labor	atory		
		Manuals, 1991.				
	297	Sasisekharan et al. "Cloning and Expression				
	1	Flavobacterium Heparinum", Proc. Natl. Aca	id. Sci. USA, 90: 3660-366	4,		
		1993.				
	298	Gordon-Cardo et al. "Expression of Basic Fil		1		
		Normal Human Tissues", Laboratory Investi	gation, 63: 832-840, 1990.			
		Abstract.				
	299	Yoshida "Effects of Basic Fibroblast Growth				
		Mouse Preimplantation Embryos", Nippon S	anka rujinka Gakkai Zassi	",		
		48(3): 170-176, 1996. Abstract.  Carson et al. Mucin and Proteoglucan Functi	t potent t describe			
	300					
		BioEssays, 20(7): 577-583, 1998. Abstract, F	7.380, Col.2 , g 2, F.382, Co	711,		
	201	Fig. 1.  Abrahamsohn et al. "Implantation and Decid	ualization in Padants" I E	vn ·		
	301	Zool., 266(6): 603-628, 1993. Abstract.	uanzation in Rodents , J. E.	.лр.		
	302	Watson et al. "A Growth Factor Phenotype N	Ann for Ouine Praimplantat	ion		
	302	Development", Biology of Reproduction, 50	(4): 725-733 1004 Abetra	-t		
	303	Novagen "PET System Manual", Novagen, 6				
	303	Ennis et al. "Rapid Cloning of HLA-A,B cD		se		
	304	Chain Reaction: Frequency and Nature of Er				
		PNAS USA, 87: 2833-2837, 1990.		,		
	305	Gilat et al. "Molecular Behaviour Adapts to	Context: Heparanase Funct	ions		
	303	as An Extracellular Matrix-Degrading Enzyr	ne or as A T-Cell Adhesion			
	ĺ	Molecule, Depending on the Local PH", Jou				
	1	181: 1929-1934, 1995.	•			
	306	Murphy et al. "The Latent Collagenase and C	Gelatin of Human			
		Polymorphonuclear Neutrophil Leucicytes",				
		1980.				
	307	Chubet et al. "Vectors for Expression and Se	cretion of FLAG Epitope-			
	1	Tagged Proteins in Mammalian Cells", BioT		96.		
	308	Chang et al. "Differential Ability of Heparan	Sulfate Protecoglycans to			
	1	Assemble the Fibroblast Growth Factor Reco	eptor Complex In Situ", FA	SEB		
		Journal, 14: 137-144, 2000.	-			
	309	Hillier et al. "The WashU-Merck EST Project	ct", Database EMBL Acces	sion		
	1	No. N45367, XP 002198420, 1996. Abstrac				

EXAMINER: Initial if reference considered, whether or not citation is in contromance with MPEP 900. Draw like through citation in roll in conformance and not considered, include copy of copy of this form with next communication to applicant. \*Applicant's view extended appeals number 1000 miles in the conformance of 
Signature

This solication of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 30 U.S. C. 122 and 37 CFR 1.14 the collection is estimated to take 2 hours to complete, including application, preprinting and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

Approved for use through 06/30/2006. OMB 0651-0031

				Approved I	ice: U.S. DE	gn 06/30/2006. OMB 0651-0031 PARTMENT OF COMMERCE					
Under the Paperwe	ork Reduction	Act of 1995, no persons are required to respond to a	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE information unless it contains a valid OMB control number.								
		ostitute for form 1449A/PTO	Cor	nown							
	Sui	ostitute for form 1449A/FTO		Application Number 10/5							
I	NFORI	MATION DISCLOSURE	Filing Date	May 02,							
S	TATE	MENT BY APPLICANT	First Named Inventor Group Art Unit	1644	ACOBY-ZEEVI et al						
	IAIL	MENT DI MILLICIANI		Examiner Name		O, MARIANNE NMN					
	_ `	as many sheets as necessary)	1	1	O, MARGANNE MININ						
Sheet	19	Of	27	Attorney Docket Number	30337						
		OTHER PRIOR ART - NON P.	ATENTL	TTERATURE DOCUMEN	N18						
	310	Marra et al. ""The WashU-HHMI Mouse EST Project", Database EMBL, Accession No. Al122034, XP 002198426, 1998. Abstract.									
		Accession No. Al122034, XP 0021	198426, 19	998. Abstract.							
	311	Marra et al. "The WashU-HHMI M			.						
		Accession No. AA047943, XP002	198424, 1	996.							
	312	Evans et al. "Human Chromosome 11 187a8 Cosmid, Complete Sequence", Database EMBL, Accession No. U73640, XP002198427, 1996. Abstract.									
	313	Suggs et al. "Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human β2-Microglobulin", Proc.									
		Isolation of Cloned cDNA Sequence	ces for Hi	iman pz-Microgioouin , r	TOC.						
		Natl. Acad. Ssci. USA, 78(11): 66	13-6617,	1981. P.0013.							
	314	Ehle et al. "Immunoaffinity Chromatography of Enzymes", Bioseparation,									
	315	1(2): 97-110, 1990.	o and Tm	fficking of Extracellular							
	313	Nadav et al. "Activation, Processing and Trafficking of Extracellular Heparanase by Primary Human Fibroblasts", Journal of Cell Science,									
		Heparanase by Primary Human Florobiasts", Journal of Cell Science,									
	316	Goldshmidt et al. "Cell Surface Expression and Secretion of Heparanase									
	310	Markedly Promote Tumor Angiogenesis and Metastasis", Proc. Natl. Acad.									
		Sci. USA, 99(15): 10031-10036, 2	002	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,							
	317	Guo et al. "Protein Tolerance to Random Amino Acid Change", PNAS,									
	1 317	101(25): 9205-9210, 2004.									
	218	Dibring "P.T. P.C.P. Method & Applications" Clanatech Laboratories, Lst. Ed.									
		1: 11, 15, 23, 41, 26, 1991.									
	319	Zcharia et al. "Heparanase Regulat									
		Journal of Pathology, 166(4): 999-									
	320	Zhu et al. "Development of Herita	The								
		Journal of Investigative Dermatolo									
	321	Duff "Transgenic Mice Overexpre	ssing Pres	senilin cDNAs: Phenotype	and						
		Utility in the Modeling of Alzhein	ner's Disea	ase", Central Nervous Syst	em						
	1	Diseases, P.123-128, 2000. Abstra	ict.								
	322	Doetschman "Interpretation of Phe	enotype in	Genetically Engineered N	fice",						
		Laboratory Animal Science, 49(2)	: 137-143	, 1999.							
	323	Wall "Transgenic Livestock: Prog	ress and F	rospects for the Future",							
		Theriogenology, 45: 57-68, 1996.									
	324	Mullins et al. "Fulminant Hyperter	nsion in T	ransgenic Rats Harbouring	the						
		Mouse Ren-2 Gene", Nature, 344:	541-544,	1990.							
	325	Hammer et al. "Spontaneous Infla	mmatory	Disease in Transgenic Rats	3_						
		Expressing HLA-B27 and Human	?2m: An	Animal Model of HLA-B27-							
		Associated Human Disorders", Cell, 63: 1099-1112, 1990.									
	326	Taurog et al. "HLA-B27 in Inbred and Non-Inbred Transgenic Mice", The									
		Journal of Immunology, 141(11):	4020-402	3, 1988.							
				0.5	sidered	-					
Signature			_	Cor	isidered						

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. \*Applicant's arique citation designation number (opinions). \*See Kridas Codes of USPTO Patent Documents at year, usafe, page on Well PPP 90.10.4. \*Einst Office that issued the document, by the voletter code (VMPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the region of the "green round precede the sential number of the patent document. \*Year of the document under which appropriate symbols as indicated on the document under WIPO Standard ST. 16 (possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1,97 and 1,98. The information is required to obtain or relain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. Ihis collection is estimated to take 2 hours to complete, including ashering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Application Number 10/559,925 Filing Date May 02, 2006 INFORMATION DISCLOSURE Oron YACOBY-ZEEVI et al First Named Inventor STATEMENT BY APPLICANT 1644 Group Art Unit Evaminer Name DIBRING MARIANNE NMN (use as many sheets as necessary) Of 27 Attorney Docket Number Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS 327 Pearce et al. "Development of Glucose Intolerance in Male Transgenic Mice Overexpressing Human Glycogen Synthase Kinase-3? on A Muscle-Specific Promoter", Metabolism, 53(10): 1322-1330, 2004. 328 Li et al. "In Vivo Fragmentation of Heparan Sulfate by Heparanase Overexpression Renders Mice Resistant to Amyloid Protein A Amyloidosis", PNAS, 102(18): 6473-6477, 2005. Zcharia et al. "Heparanase Acclerates Wound Angiogenesis and Wound 329 Healing in Mouse and Rat Models", The FASEB Journal, 19: 211-221, 2005. Zcharja et al. "Molecular Properties and Involvement of Heparanase in 330 Cancer Progression and Mammary Gland Morphogenesis", Journal of Mammary Gland Biology and Neoplasia, 6(3): 311-322, 2001. Nadir et al. "Co- Interaction and Increased Release of Tissue Factor Pathway Inhibitor by Heparanase", Blood, 106(11/Part 2): 90B, 2005. Abstract# 4038. Spiegel et al. "Heparanase Facilitates Development and SDF-1 Induced 332 Migration of Hematopoietic Stem and Progenitor Cells", Blood, 102(11): 825a-826a, 2003. Abstract# 3056. Zcharia et al. "Transgenic Expression of Mammalian Heparanase Uncovers Physiological Functions of Heparan Sulfate in Tissue Morphogenesis, Vascularization, and Feeding Behavior", The FASEB Journal, 18: 252-263, 2004. Nasser et al. "Heparanase Neutralizes the Anticoagulation Properties of 334 Heparin and Low-Molecular-Weight Heparin", Journal of Thrombosis and Haemostasis, 4: 560-565, 2006. Mullins et al. "Expression of the DBA/2J Ren-2 Gene in the Adrenal Gland of Transgenic Mice", The EMBO Journal, 8(13): 4065-4072, 1989. 336 McKenzie et al. "Biochemical Characterization of the Active Heterodimer Form of Human Heparanase (Hpa1) Protein Expressed in Insect Cells", Biochemical Journal, 373: 423-435, 2003. Nakajima "Heparanases and Tumor Metastasis", Tanpakushitsu Kakusan Koso, 37(11): 1753-1758, 1992. Abstract. Ricoveri et al. "Heparan Sulfate Endoglycosidase and Metastatic Potential in 338 Murine Fibrosarcoma and Melanoma", Cancer Research, 46(8): 3855-3861, 1986, Abstract. Wight et al. "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9(1): 339 1-20, 1989. Vlodavsky et al. "Expression of Heparanase by Platelets and Circulating 340 Cells of the Immune System: Possible Involvement in Diapedesis and Extra

\*EXAMMER: Initial if inference considered, whether or not clasion is in conformance with MPEP 809. Draw line through catalin in fruit conformance and not considered, include capy of copy of this from with nest communication to applicant. \*Applicant value cataline designation under (soldered.) \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.usor.org/winds/fisher/de

Vasation", Invasion & Metastasis, 12(2): 112-127, 1992, Abstract.

Signature

Transarion is stractived.

157 To the Company of th

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pape	rwork Reduction	Act of 1995, no persons are required to respond to a collection of	f information unless it contains a valid C	OMB control number						
	Su	bstitute for form 1449A/PTO	Complete if Known							
			Application Number	10/559,925						
	INFOR	MATION DISCLOSURE	Filing Date	May 02, 2006						
	STATE	MENT BY APPLICANT	First Named Inventor	Oron YACOBY-ZEEVI et al						
	SIAID	MENT DI ATTERCANT	Group Art Unit							
	,	as many sheets as necessary)	Examiner Name	DIBRINO, MARIANNE NMN						
Sheet	21	Of 27 Attorney Docket Number 30337								
		OTHER PRIOR ART – NON PATENT		ITS						
	341	Vlodavsky et al. "Lymphoma Cell-Mediate								
	1	Proteoglycans in the Subendothelial ExtraC		to						
		Tumor Cell Metastasis", Cancer Research,	43: 2704-2711, 1983.							
	342	Vlodavsky et al. "Involvement of Heparana	se in Tumor Metastasis and	1						
		Angiogenesis", Isr. J. Med. Sci., 24(9-10):	464-470, 1988.	1						
	343	Vlodavsky et al. "Morphological Appearan								
	•	Migratory Activity of Human Tumor Cells Maintained on Extracellular								
		Matrix Versus Plastic", Cell, 19: 607-616, 1980.								
	344	Vlodavsky et al. "Extracellular Sequestration and Release of Fibroblast								
		Growth Factor: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-								
	1	271, 1991.								
	345	Ishai-Michaeli et al. "Importance of Size and Sulfation of Heparin in Release								
	343	of Basic Fibroblast Growth Factor From the Vascular Endothelium and								
	346	ExtraCellular Matrix", Biochemistry, 31(7): 2080-2088, 1992. Abstract.  Haimovits-Friedman et al, "Activation of Platelet Heparitinase by Tumor								
	346	Cell-Derived Factors", Blood, 78(3): 789-796, 1991.								
	347	Miao et al. "Modulation of Fibroblast Gro		na -						
	347	Miao et al. Modulation of Fibrobiast Gio	ativity by A Symthetic Hono	roin						
	1	Dimerization, Signaling, and Angiogenic Activity by A Synthetic Heparain- Mimicking Polyaromatic Compound", J. Clin. Invest., 99(7): 1565-1575,								
			iii. iiivest., 99(7). 1303-137	3,						
		1997.	al Pastan Madiated Automi							
	348	Benezra et al. "Reversal of Fibroblast Growth Factor-Mediated Autocrine Cell Transformation by Aromatic Anionic Compounds", Cancer Research,								
			Compounds, Cancer Resear	ren,						
		52: 5656-5662, 1992.								
	349	Irimura et al. "Chemically Modified Hepar	ins as inhibitors of Heparan							
		Sulfate Specific Endo-β-Glucuronidase (H	eparanase) of Metastatic							
		Melanoma Cells", Biochemistry, 25: 5322-	5328, 1986. Abstract.							
	350	Coombe et al. "Analysis of the Inhibition of	f Tumor Metastasis by Sulp	hated						
		Polysaccharides", Int. J. Cancer, 39: 82-88	, 1987. Abstract.							
	351	Ornitz et al. "Heparin Is Required for Cell-								
	- 1	Growth Factor to A Soluble Receptor and		ells",						
	I	Molecular and Cellular Biology, 12: 240-2								
	352	Yayon et al. "Cell Surface, Heparin-Like N	Iolecules Are Required for							
		Binding of Basic Fibroblast Growth Factor	to Its High Affinity Receptor	or",						
		Cell, 64: 841-848, 1991.								
	353									
		Sulfate Proteoglycans That Promote Bindi	ng of Basic Fibroblast Grow	th						
		Factor to Its Receptor", J. Biol. Chem., 26	9(1): 114-121, 1994.							

\*EDAMMEN: missi infestrence considered, whether or not calabon is in conformance with MPEP 609. Draw their through classlor of not conformance and not considered involved copy of copy of this form with next communication to applicant, "Applicant as many classification number (coloration number (coloration) as extended or USPTO Desent Documents at two sussification or of MPEP 901.04. "Enter Office that issued the document, by the two-letter code (MPIPO Standard ST.3). "For Lapances point document, by the two-letter code (MPIPO Standard ST.3)." "For Lapances point document, the indication of the year of the region of the Emperor must proceed the sestial number of the patient document, but microscopic and the sestial number of the patient document. "Red of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible." Applicant is to place a check mark here if English language Transation is satisfact.

Signature

The solution of the public which is feeler only in the solution of the public which is feeler of by the form of the solution of the sentiment of the public which is feeler of the solution of the sentiment of th

Approved for use through 06/30/2006, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

						ce: U.S. DEPARTMENT OF COMMERCE				
Under the Pape	work Reduction	Act of 1995, no persons a	c required to respond to a coll	lection of	information unless it contains a valid C	omber if Known				
	Sub	stitute for form 1449A/P	то	Application Number	10/559,925					
1			or ourms		Filing Date	May 02, 2006				
1	INFORM	AATION DIS	CLOSURE	First Named Inventor	Oron YACOBY-ZEEVI et al					
	STATE	MENT BY AI	PPLICANT	Group Art Unit	1644					
				Examiner Name	DIBRINO, MARIANNE NMN					
	(use a	is many sheets as r	necessary)	Examiner Hame						
Sheet	22		Of	27	Attorney Docket Number	30337				
					ITERATURE DOCUMEN	ITS				
	354	Bartlett et al. " C	omparative Analysis	of the	Ability of Leucocytes,					
		Endothelial Cells	, and Platelets to Deg	grade th	ne Subendothelial Basemen	it				
		Membrane: Evid	ence for Cytokine De	epender	nce and Detection of A Nov	vel				
			inology and Cell Bio							
	355				Heparanase: Its Applicatio					
		Assay of Human	Melanoma for Hepa	ran Sul	fate Degradative Activity",					
		Analytical Bioch	emistry, 157: 162-17	1, 1986	5.					
	356	Oosta et al. "Pur	ification and Properti	es of H	uman Platalets Heparitanas	se", J.				
1			(19): 11249-11255,							
	357	Sewell et al. "Hu	man Mononuclear C	ells Co	ntain An Endoglycosidase					
	1	Specific for Hep	aran Sulfate Glycosa	minogh	yean Demonstrable With th	ne Use				
		of A Specific Solid-Phase Metabolically Radiolabelled Substrate", Biochem								
		J., 264: 777-783, 1989.								
	358	Freeman et al. "A Rapid Quantitative Assay for the Detection of Mammalian								
		Heparanase Activity", Biochemical Journal, 325: 229-237, 1997.								
	359	Taylor et al. "A Colorimetric Method for the Quantitation of Uronic Acids								
		and A Specific Assay for Galacturonic Acid", Analytical Biochemistry, 201:								
		190-196, 1992.								
	360				by Fluorophore-Assisted					
					de Glycanase From Mercer	naria				
		Mercenaria", Analytical Biochemistry, 222: 270-274, 1994.								
	361	Jackson "The Use of Polyacrylamide-Gel Electrophoresis for the High-								
		Resolution of Separation of Reducing Saccharides Labelled With the								
				, 6-Tris	sulphonic Acid", Biochem J	J.,				
		270: 705-713, 19	90.							
	362				4/Endoplasmin From A KN					
١,,	amda -				s Directed Against A Putat					
7.0	-				. Cancer, 56: 286-294, 199	4.				
	363	Goldberg et al. "	An Improved Method	d for D	etermining Proteoglycans					
		Synthesized by 0	Chondrocytes in Cult	ure", Li	ive Tissue Research, 24: 26	55-				
		275, 1990.								
	364				e, Growth Behaviour and					
					Maintained on Extracellular					
		Matrix Versus P	lastic", Cell, 19: 607-	-616, 19	980.					
	365				es Binding of Lipoproteins	to				
					ellular Matrix", Journal of					
		Clinical Investig	ation, 90: 2013-2021	, 1992.						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy or do only of this form with next communication to applicant. \*Applicant's induce intention designation number (optional). \*See Kinds Codes or USPI'O Paelin Counteris at www.nexto.goo.or or NEP 001 0.4. \*Einst Office be at lassand the value counter, by the "host letter code (VIPO 3 parties) and "Service of the "feet" of the "Feet" appeares patient documents. The indication of the year of the reign of the Emperor number of see an annuals of the and with the control of the counter of the counter of the control of the counter 
Signature

Iransiation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fit (and by the This collection of information is required by 30 LS C. 122 and 1.98. The information is not information in the information of the information o

Approved for use through 06/30/2006. OMB 0651-0031

		,	,	U.S. Patent and Trademark Office	ce: U.S. D.	igh 06/30/2006. OMB 0651 EPARTMENT OF COMMI				
Under the Pape	rwork Reduction	Act of 1995, no persons are required to respond to a	a collection of	information unless it contains a valid C	MB control	number.				
	Sul	stitute for form 1449A/PTO			lete if Kn 10/559.					
					., 2006					
	INFOR	MATION DISCLOSURE	Filing Date First Named Inventor		ACOBY-ZEEVI et al					
	STATE	MENT BY APPLICANT		Group Art Unit	1644	ACOB I -ZEEVI CI al				
	517112	TELLI DI MITELENIA		Examiner Name		NO. MARIANNE NMN				
	(use	is many sheets as necessary)				10, MAIGANNE NIM				
Sheet	23	Of	27	Attorney Docket Number	30337					
		OTHER PRIOR ART - NON P.	ATENT L	ITERATURE DOCUMEN	TS					
	366	Gitay-Goren et al. "The Binding of	f Vascular	Endothelial Growth Factor	to Its					
		Receptors Is Dependent on Cell Su	ırface-Ass	ociated Heparin-Like	i					
		Molecules", Journal of Biological Chemistry, 267(9): 6093-6098, 1992.								
	367	Matzner et al. "Degradation of Her	paran Sulf	ate in the Subendothelial						
	1	Extracellular Matrix by A Readily								
		Neutrophils", Journal of Clinical I			. 1					
	368	Mollinedo et al. "Major Co-Localiz								
	1500	Degradative Enzymes Heparanase	and Gelat	inase in Tertiary Granules	of					
	1	Human Neutrophils", Biochemical			1					
	369	Narindrasorasak et al. "High Affin								
	309	Amyloid Precursor Proteins and								
					,,,,,,,					
	370	Sulfate Proteoglycan", J. Biol. Chem., 266(20): 12878-12883, 1991.  Zhong-Sheng et al. "Role of Heparan Sulfate Proteoglycans in the Binding								
	370	and Uptake of Apolipoprotein E-E	nriched P	empant Lipoproteins by Cu	ltured					
		Cells", J. Biol. Chem., 268(14): 10	1160-1016	7 1003						
	371	Hudson "Recombinant Antibody F	ragment"	Curr Onin Biotech 4:39	5-					
	3/1	402, 1998, Abstract.	raginent	Curr. Opin. Diotecti., 4.57	١ ١					
	372	Schoepe et al. "Neutralization of H	Iamolytic	and Mouse Lethal Activitie	s of					
	312	C. Perfringens Alpha-Toxin Need	Cimultone	our Blockage of Two Enite	nes					
		by Monoclonal Antibodies", Micro	oh Dothoo	onesis 22(1): 1-10 1907	pes					
		Abstract.	oo. ramog	ellesis, 23(1). 1-10, 1997.						
	373	Mateo et al. "Humanization of A N	Acuse Ma	neelenal Antibody That Di	ocks					
	3/3	the Epidermal Growth Factor Rece	viouse Mo	avenu Antagonistic Activity	,"					
		the Epidermai Growth Factor Reck	epior. Rec	Antagonistic Activity	',					
	251	Immunotechnology, 3: 71-81, 199 Nakajima et al. "Heparanases and	T. Abstrac	t.	ar					
	374			etastasis , Journal of Cellul	aı					
	200	Biochemistry, 36(2): 157-167, 198  Ngo et al. "Computational Comple		-i- Campatona Duadiation on	d tho					
	375	Levinthal Paradox", The Protein F	exity, Prot	the Structure Frediction, an	u tile					
		Levininai Paradox", The Protein P	422 402	os 1004						
		Prediction, Birkhauser, Boston, P Lederman et al. "A Single Amino	433, 492-	193, 1994.						
	376	Lederman et al. "A Single Amino	Acid Subs	citution in A Common Airi	can					
		Allele of the CD4 Molecule Ablate	es Binding	g of the Monocional Antibo	uy,					
		OKT4", Molecular Immunology, 2	28: 11/1-1	181, 1991.	f. 14.					
	377	Li et al. "β-Endorphin Omission A	nalogs: D	issociation of immunoreact	ivity					
		From Other Biological Activities"	, PNAS, /	1: 3211-3214, 1980.						
	378	Marchetti et al. "Neurotrophin Stir	mulation o	f Human Melanoma Cell						
		Invasion: Selected Enhancement of	of Heparan	ase Activity and Heparana	se .					
		Degradation of Specific Heparan S	Sulfate Su	populations", Cancer Rese	arcn,					
		56: 2856-2863, 1996. Also in: Adv	vances in	Enzyme Regulation, 37: 11	1-134,					
		1997.								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. \*Applicant's -equip citation designation number (optional), \*3ee Kinds Codes of USPTO Patent Opcoments a two-wastopox or MEPP 001 0.4. \*Either Clother but alsued the document, by the volter code (VIPP 05 patent) and support of the property of the proper Translation is attached.

Signature

Iransation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the Tiss collection of Information is required by 3.91 CFR 2.22 and 3.7 CFR 1.18 is collection to its settlemed to like 2 hours to complete, finding USPTO to process) an application. Confidentially is governed by 3.91 CFR 2.22 and 3.7 CFR 1.18 is collection to settlemed to like 2 hours to complete the including to complete the including to complete the including to complete the including to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of line you require to complete this form and/or suggestions for reducing this budge, not upon a ent to the Chief Information Officer, Leptart and Trademark Office, US. Department of commerce, P.O. Box 1450, Alexandria, V.X 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, V.X 22313-1450.

Substitute for form 1449A/PTO

394

395

Signature

Approved for use through 06/30/2006, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

10/559,925 Application Number May 02, 2006 Filing Date INFORMATION DISCLOSURE First Named Inventor Oron YACOBY-ZEEVLet al STATEMENT BY APPLICANT Group Art Unit Examiner Name DIBRINO, MARIANNE NMN (use as many sheets as necessary) Attorney Docket Number Of 27 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Kosir et al. "Human Prostate Carcinoma Cells Produce Extracellular 379 Heparanase", Journal of Surgical Research, 67: 98-105, 1997. Köhler et al. "Continuous Cultures of Fused Cells Secreting Antibody of 380 Predefined Specificity", Nature, 256: 495-497, 1975. Hulett et al. "Cloning of Mammalian Heparanase. An Important Enzyme in 381 Tumor Invasion and Metastasis", Nature Medicine, 5(7): 803-809, 1999. Toyoshima et al. "Human Henaranase: Purification, Characterization, Cloning, 382 and Expression", J. Biolog. Chemistry, 274(34): 24153-24160, 1999. Kussie et al. "Cloning and Functional Expression of A Human Heparanase Gene", 383 Biochemical and Biophysical Research Communication, 261(1): 183-187, 1999. Walch et al. "Correlation of Overexpression of the Low-Affinity p75 384 Neutrotrophin Receptor With Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", Int. J. Cancer, 82: 112-120, 1999. Freeman et al. "Evidence That Platelet and Tumour Heparanases Are Similar 385 Enzymes", Biochem J., 342: 361-368, 1999. Suppl. IDS in 25783; Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in 386 Biochemistry and Molecular Biology, 30(5): 387-444, 1995. Zhou et al. "A 182 Bp Fragment of the Mouse Proal(11) Collagen Gene Is 387 Sufficient to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science, 108: 3677-3684, 1995. Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First 388 Intron in Expression of the a1 (1) Collagen Gene.", Mol Cell Biol., 18(6): 3368-3375, 1998, Abstract. Chow et al. "Development of An Epithelium-Specific Expression Cassette With 389 Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci. USA, 94: 14695-14700, 1997. Ye et al. "Targeted Gene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today, P.431-437, 1998. Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 391 7(1):11-14, 1999, Abstract. Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of 392 Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy". Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997. Shastry "Gene Disruption in Mice: Models of Development and Disease", 393 Molecular and Cellular Biochemistry, 181: 163-179, 1998.

EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered, include copy of copy of this form with next communication to applicant. "Applicant's enque cliation designation number (options)." See Kinds Codes or (USPTO Patient) Documents at www.uselgo.gov or MPEP 901-0.4. "Either Clieb that issued the document, by the work letter code (VMPE) Sarting 451-31.
"For Japanese patent documents, the indication of the year of the region of the Emperor must precede the sental number of the patient document." Year of communications of the patient document is preceded by the appropriate symbols as indicated on the document under WIPD Standards 37: 16 prossible. "Applicant is to place a rebet mark here if English language Translation is attached.

Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A

Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824. 1998. Lai et al. "DNA Vaccines", Critical Reviews in Immunology, 18: 449-484, 1998.

Transation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to the 2 Pours to complete, including pathering, preparing, and submitting the completed application from to the USPTO. Time will way depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Olicer, U.S. Pathert and Trademark Ortice, U.S. Department of commerce, P.O. Box 1450, Alexandria, Az 2313-1450, D.O. NOT SEND TESS OR COMPLETED PORTMS TO THIS ADDRESS.

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known						
Application Number	10/559,925					
Filing Date	May 02, 2006					
First Named Inventor	Oron YACOBY-ZEEVI et al					
Group Art Unit	1644					
Examiner Name	DIBRINO, MARIANNE NMN					

	(use	e as many sneets as necessary)									
Sheet	25	Of	27	Attorney Docket Nur	nber	30337					
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS									
	396	Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic									
		Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14: 27-37,									
		1994/5.									
	397	Durand et al. "Active-Site Motifs of L									
		GH-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", Glycobiology,									
			7(2): 277-284, 1997.								
	398	Korb et al. "Stimulation of Gene Expr									
		to A Stimulatory Intron by Alteration	of the	Splice Donor Sequen	ice", N	ucleic Acids					
		Research, 21(25): 5901-5908, 1993.									
	399	Fairbanks et al. "Processing of the Hu	man H	eparanase Precursor	and Ev	idence that the					
		Active Enzyme Is A Heterodimer", TI	ne Jour	nal of Biological Che	emistry	7, 274(42): 29587-					
	100	29590, 1999.  Linhardt et al. "Polysaccharide Lyases		P. I D'. L	1 Di	h1 12: 126					
	400		s", App	ited Biochemistry an	ia Biot	echnology, 12: 133-					
	401	176, 1986.	ti-1 Da	vulatan af CallMutain	Intono	ations!! TIDS					
	401	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000, P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.									
	402					A Novel					
	402	Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", Gene, 108(2): 193-199, 1991. Abstract.									
	403	Mirault et al. "Transgenic Glutathione Peroxidase Mouse Models for Neuroprotection									
	403	Studies", Ann. NY Acad. Sci., 738: 104-115, 1994. Abstract.									
	404	Lampard et al. "Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene									
	104	Regulatory Sequences", Biochem. Cell Biol., 80(6): 777-788, 2002. Abstract.									
	405	Morrison et al. "Sequences in Antiboo	iv Mol	ecules Important for	Recept	tor-Mediated					
		Transport Into the Chicken Egg Yolk'									
	406	Richards et al. "Construction and Prel									
		Lactalbumin cDNA Clones", J. Biol.									
	407	Campbell et al. "Comparison of the W	hey A	cidic Protein Genes o	of the F	Rat and Mouse",					
		Nucleic Acids Res., 12(22): 8685-8697, 1984.									
	408	Gorodetsky et al. "Isolation and Chara	acteriza	tion of the Bos Tauri	us β-C	asein Gene", Gene,					
		66: 87-96, 1988. Abstract.									
	409	Benezra et al. "Thrombin Enhances th									
		Matrix by Tumor Cell Heparanase", E	Exptl. C	cell. Res., 201: 208-2	15, 19	92.					
	410	Harlow et al. "Antibodies - A Laborat	tory Ma	anual", Cold Spring I	Iarbor	Press, P. 471-510,					
		1988.	_								
	411	Murray et al. "The Extracellular Matr			McGr	aw-Hill					
	-	Professional, 24th Ed., Chap.57, P.66	7-685,	1998.		7 . 707 127 126					
	412	Selvan et al. "Heparan Sulfate in Imm	nune Re	esponses", Ann. NY	Acad.	Sci., /9/: 127-139,					
	1	1996.		u c Martani	inate mi						
1	413	Prockop "Marrow Stromal Cells as St	em Ce	us for Nonhematopoi	ietic l'i	issues", Science,					
		276: 71-74, 1997.									
Ci.	-				Consid	darad					
Signature	l				Consid	ucicu					

EXAMINER: Initial if reference considered, whether or not citation is in continuous and INPEP 909. Draw this through citation if not in conformance and not considered, include copy of copy of this form with rest communication to applicant. Applicant's inique citation designation number (postions). See Kinds Code of USPTO Patent Occurrents a stewards2002 of Preservation of the Common of the Common of the Code of

This collection of information is required by 3T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CPR 1.14 this collection is estimated to bits 2-bit complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your exquire to complete its notions for reducing this upone, and the complete the information officers, USP 2-bit and Trademark Officer.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMI	
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.	

Under the Paperw	vork Reductio	n Act of 1995, no persons are required to respond to a coll	ection of	information unless it contains a valid C	MB control no	moer.				
	Su	bstitute for form 1449A/PTO	Complete if Known Application Number 10/559.925							
				Application Number	May 02, 2006					
I	INFOR	MATION DISCLOSURE	Filing Date First Named Inventor	Oron YACOBY-ZEEV1 et al						
9	STATE	MENT BY APPLICANT	Group Art Unit	1644	COBY-ZEEVI et al					
	JIAIL	MENT DI ATTEMIT	Examiner Name		, MARIANNE NMN					
	(use	as many sheets as necessary)			, MARIANNE NWIN					
Sheet	26	Of	27	Attorney Docket Number	30337					
		OTHER PRIOR ART - NON PAT	ENT L	ITERATURE DOCUMEN	TS					
	414	Pomahac et al. "Tissue Engineering of	f Skin"	Crit. Rev. Oral Biol. Med.	,					
		9(3): 333-344, 1998. Abstract.								
	415	Benathan et al. "Living Epidermal and	l Derm	al Substitutes for Treatmen	t of					
		Severely Burned Patients", Rev. Med.	Suisse	Romande, 118(2): 149-15;	3. l					
		1998. Abstract-			.					
	416	Wang et al. "Basic Fibroblast Growth	Factor	Enhances Bone-Graft						
	1	Incorporation: Dose and Time Depend	lence i	n Rats", J. Orthop. Res., 140	2):					
		316-323, 1996. Abstract.								
	417	Garner "Epidermal Regulation of Dermal Fibroblast Activity", Plast.								
	717	Reconstr. Surg., 102(1):135-139, 199								
	418	Raghunath et al. "Cultured Epithelial Autografts: Diving From Surgery Into								
	410	Matrix Biology", Pediatr. Surg. Int., 1	2(7): 4	78-483 1997 Abstract						
	419	Maillard et al. "Pre-Treatment With Elastase Improves the Efficiency of								
	417	Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media",								
		Gene Therapy, 5: 1023-1030, 1998.								
	420	Wang "Basic Fibroblast Growth Factor for Stimulation of Bone Formation in								
	420	Osteoinductive or Conductive Implants", Acta Orthop. Scand. Suppl., 269: 1-								
		33, 1996, Abstract.								
	421	Wang "Basic Fibroblast Growth Factor	na							
	421	Bone Graft Incorporation. Titanium C	on l							
		Scand., 67(3): 229-236, 1996. Abstract	. Г							
	422	Aspenberg et al. "Fibroblast Growth I								
	422	Bone Induction Studied in Rats", Acta	Ortho	n Scand 60(4): 473-476	1080					
		Abstract.	Office	p. 3cand., 00(4). 473-470,	1707.					
	423	Aspenberg et al. "Dose-Dependent St	imulati	on of Bone Induction by B	eic					
	423	Fibroblast Growth Factor in Rats", Ac	imuiau	on Coand 62(5): 481-484	asic					
			la Orti	iop. Scalid., 02(3). 461-464	',					
	424	1991. Abstract.  Matoba et al. "Evaluation of Omental	ic							
	424	Ulcer Therapy: Findings in A Rat Mo	Costroportoral 21(6): 777	794						
			der, J	Gastroenterol., 31(6): ///	-704,					
		1996. Abstract.								
01				Cone	idered					
Signature	1	1		Cons	idered					

EXAMINER: Initial if reference considered, whether or not citation is in continuance with MPEP 900. Druw line through station if not in conformance and not considered include copy of this form with linest communication to applicant. Applicant's enjoyed citation feeting below the property of the Proper

Iranuaron is anisched.
This collection of information is required by 37 CFF 1.97 ms 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information) is required to obtain or retain a benefit by the solic control is estimated to take 2 to complete including USFT 00 is process) an application. Confidentially is governed by 34 U.S. CF. 22 and 27 CFR 1.4 this collection is esternated to take 2 to complete the including USFT 0.5 the will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or supprecisions for reducing this budden, about be seen to the Chief Information Officer, US. Patent and Trademark Office, US. Department of commence, P.O. 80x 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VA 22313-1450.

09/25/2009

Considered

#### PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Application Number 10/559,925 Filing Date May 02, 2006 INFORMATION DISCLOSURE Oron YACOBY-ZEEVI et al First Named Inventor STATEMENT BY APPLICANT Group Art Unit 1644 Examiner Name DIBRINO MARIANNE NMN (use as many sheets as necessary) Attorney Docket Number Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS 425 Aplin "Adhesion Molecules in Implantation", Reviews of Reproduction, 2(2): 426 Lessey et al. "Paracrine Signaling in the Endometrium; Integrins and the Establishement of Uterine Recentivity", J. Reprod. Immunol., 39(1-2): 105-116, 1998, Abstract. Burrows et al. "Trophoblast Migration During Human Placental 427 Implantation", Hum. Reprod. Update, 2(4): 307-321, 1996. Bischof et al. "The Regulation of Endometrial and Trophoblastic 428 Metalloproteinases During Blastocyst Implantation", Contracept Fertil Sex, 22(1): 48-51, 1994, Abstract, 429 Smith et al. "Expression of Henaran Sulfate Protoglycan (Perlecan) in the Mouse Blastocyst Is Regulated During Normal and Delayed Implantation", Dev. Biol., 184(1): 38-47, 1997. Abstract. Abaza et al. "Effects of Amino Acid Substitutions Outside An Antigenic Site 430 on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration With Region 94-100 (Antigenic Site 3) of Myoglobin", Journal of Protein Chemistry, 11(5): 433-444, 1992,

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Induse copy of this form with next communication to applicant.

"Applicant surject existence design existence in the property of the communication of the property 
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

/Marianne DiBrino/

Signature



ETE 77

BEST AVAILABLE COPY 195 2006 B

PTO/SB/08A (10-96)

Please type a plus sign (+) inside this box → +

Examiner

Approved for use through 10/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of i formation unless it contains a valid OMB control number. Complete if Known

#### Substitute for form 1449A/PTO 10/456,573 Application Number 06/09/2003 Filing Date INFORMATION DISCLOSURE Iris PECKER First Named Inventor STATEMENT BY APPLICANT 1646 Group Art Unit Examiner Name

(use as many sheets as necessary)

		(			Of		2	Attorney Docket Number	25677
Sheet	1				I'S I				
Examiners Cite		U.S. Patent Document  Number Kind Code <sup>2</sup> (if known)			Name of Patentee or Amplicant of Cited Docume ut			Date of Publication of Cited Document MM-DD-YYYY 01-23-2001	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		6,177			Pecker et			10-19-1999	
	~	5,968			Pecker et			12-16-2003	
	< <		4,105		Pecker et			06-05-2001	
	7	6,242	2,238	<u></u>	Freeman e	t al		00-03-2001	
				<u> </u>				NITTO :	
						GN PATI	ENT DOCUME	.N13	
Examiners Initials	Cite No. 1	Office <sup>3</sup>	Number	nt Doc	Kind Code <sup>5</sup> (if known)	Applicar	ne of Patentee or nt of lited Docume	MM-DD-1111	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
	1	wo	03/006	645		IMCLOI	NE: YSTEMS	01-23-2003	
			-					1	1

Signature EXAMINER, Initial if reference considered, whether or not citation is in conformance vith MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicar t.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time v ill vary depending upon the needs of the individual case. Any comments on the amount of time, you are required to complete this form should be sent to the Chief Information Officer, Platent and Trademark Office.

on the stricture you are required to complete this form about the bank of the stricture of

Date

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Document. <sup>3</sup> Enter Office that assued the document, by the two-letter code (WIPO Standard ST.S.) <sup>2</sup> For Jupanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Forth of occument by the appointed symbols as indicated on the document under WIPO Standard ST. 16 if possible <sup>6</sup> Applicant is to place a check mark here it English banguage Translation i attached.



# BEST AVAILABLE 18558925 - GAU: 1644

PTO/SB/08A (10-96)

Please type a plus sign (+) inside this box → 🗵 Approved for use through 10/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of i formation unless it contains a valid QMB control rur then

# Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known 10/456.573 Application Number 06/09/2003 Filing Date First Named Inventor Iris PECKER Group Art Unit /Marianne DiBrino/ Examiner Name

	(	use as many sheets as necessary)	Examiner Name	/Widifallife Dibili						
heet	1 2	Of 2	Attorney Docket Number	25677						
Heet		OTHER PRIOR ART - NON PATI NT LITE	RATURE DOCUMENTS							
xaminer	Cite	CAPITAL LETTER A title of the	e article (when appropriate), title:	of the per(s).						
nitials	No.1	include name of the author (in CAFTING, CETTING), item (book, maguzine, journal, serial symposium, c stalog, etc.) date, pagets), volume-issue number(s), publisher, city and/or e- unity where published.								
intiais	110.	s of								
	1 /	Vlodavsky et al, "Inhibition of tumor meta tasis by h	202 (abetract)							
	`	heparin", Invasion Metastasis. 1994-95;14 1-6):290-302 (abstract)  Parish et al, "Evidence that sulphated poly: accharides inhibit tumour metastasis by								
		Parish et al, "Evidence that sulphated poly: acchange	1097 Oct 15:40(4):51	1-8						
		blocking tumour-cell-derived heparanases'. Int J Ca	discourse and prolongation	nof						
	1	Lider et al, "Suppression of experimental autoimmur	te diseases and protongano	west						
	1 1	allograft survival by treatment of animals with low d	oses of neparitis, 5 cm. in							
		1989 Mar;83(3):752-6.		Blood						
	1 /	Gewirtz et al, 'Nucleic acid therapeutics: state of the	art and tutute prospects ,	, , , , , , , , , , , , , , , , , , ,						
		1998 Aug 1:92(3):712-36. Hida et al, "Antisense E1AF transfection r:strains oral cancer invasion by reducing								
	1	Hida et al, "Antisense El AF transfection r strains of	202 1 150(6):2125 22	·······						
	v	matrix metalloproteinase activities", Am J Pathol. 19	997 Jun; 130(0).2123-32							
		(abstract)	um i di bis balia							
		Thuong et al, "Sequence-specific recognit on and m	odification of double-fields	11						
		DNA by oligonucleotides", Angew. Chem Int. Ed. I	Engl., 32:000-090, 1993	2002						
		Cohen, JS, "Oligonucleotide therapeutics'. Trends I	7992							
		(abstract)								
	J-	Szczylik et al, "Selective inhibition of leu :emia cell								
		antisense oligodeoxynucleotides", Science 1991 Au	tract)							
		Calabretta et al, "Normal and leukemic he matopoie	II							
		sensitivity to inhibitory effects of c-myb a stisense of	1 VILTO							
	-	study relevant to bone marrow purging", i'roc Natl	Acad Sci U S A. 1991 Mar							
		15;38(6):2351-5.		T.F.						
		Burch et al, "Oligonucleotides antisense to the inter	leukin I receptor mRN blo	ck the						
	1	effects of interleukin 1 in cultured murine and hum	fibroblats and in mice, J C	.iin						
	i	Invest 88(4):1190-1196, 1991 (abstract								
		Agrawal S., "Antisense oligonucleotides : s antivira	l agents". Trends Biotechno	51.						
	, ,	10(5):152-158 199#2 (abstract)								
		Uno et al. "Antisense-mediated suppressi in of hum	an heparanase gene express	sion						
	1 /	inhibits pleural dissemination of human c incer cell	s", Cancer Res. 2001 Nov							
	1	1:61(21):7855-60.								
	i									
		1								
		i		ļ						
		!	Date							
Examiner	1		Considered							
Signature			· Considered							

EXAMINER: Initial if reference considered, whether or not dilation is in conformance vith MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should birs ent to the Chief Information Officer, Patent and Trademark Office. Washington, DC 20231.

<sup>.</sup> Unique citation designation number. 2 Applicant is to place a check mark here if Enç ish language Translation is attached.

BEST AVAILABLE 200

Please type a plus sign (+) inside this box → 🗵 Approved for use through 10/31/99 OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection PTO/SB/08A (10-96)

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many shoots as nacassam)

it contains a valid OMB control it imber.

Complete if Known Application Number 10/645,659 Filing Date 08/22/2003 First Named Inventor YACOBY-ZEEVI Group Art Unit

		(use as many sheets as necessary)		Examiner Name	/Mai	ianne DiBri
Sheet	1	Of	11	Attorney Docket Number	26128	Idillie Dibil
		OTHER PRIOR ART - N	ON PATENT LITER	ATURE DOCUMENTS		
Examiner Initials	Cite No. <sup>1</sup>	luclade name of the author (in CAPII item (hook, magazine, journal, serial s publisher,	of the ter(s).	T¹		
		Fairbanks et al, "Processing of t the Active Enzyme is a Heterodi 29590, 15 Oct. 1999.	1.7-			
		Hulctt et al, "Cloning of Mamma Invasion and Metastasis", Nature				
		Toyoshima et al, "Human Hepan Expression", J. of Biolog. Chemi 1999.	13.			
		Miao et al, "Cloning, Expression Expression and Purification, 26:	ein			
		Freeman et al, "Human Platelet F Catalytic Activity". Biochem J.,	leparanase: Purificatio 330(3): 1341-1350, 19	on, Characterization and 198.		
					$\equiv$	
					$\pm$	
kaminer gnature	/Ma	arianne DiBrino/		Date Considered		09/25/2009

<sup>&</sup>quot;XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>1.</sup> Unique citation designation number, 2. Applicant is to place a check mark here if English language Translation is attached.

Birden from Statement. This form is estimated to take 2.0 hours to complete. Time will say depending upon the needs of the individual caie. Any comments on the someties of time you are required to complete this form should be sent to the Chief Internation Officer, Patents and Trademisk Office. Washington, Dc 20231.

30 NOT SEED FEES ON COMPLETED FORMS TO THIS ADDRESS, SENDITO. Assistant Commissioner for Patents, Washington, Dc 20231.